






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 453/00, 471/18, 498/18 C07D 513/18, A61K 31/435 A61K 31/495, 31/535, 31/54 // (C07D 471/18, 241/00, 221/00 C07D 221/00) (C07D 471/18 C07D 221/00, 221/00, 209/00) (C07D 471/18, 221/00, 221/00 C07D 221/00) (C07D 498/18 C07D 265/06, 221/00, 221/00) (C07D 513/18, 279/00, 221/00, 221/00)</p>	A1	<p>(11) International Publication Number: WO 92/01688</p> <p>(43) International Publication Date: 6 February 1992 (06.02.92)</p>
<p>(21) International Application Number: PCT/US91/03369</p> <p>(22) International Filing Date: 14 May 1991 (14.05.91)</p> <p>(30) Priority data: 557,442 23 July 1990 (23.07.90) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 557,442 (CIP) Filed on 23 July 1990 (23.07.90)</p> <p>(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).</p>		<p>(72) Inventor; and (75) Inventor/Applicant (for US only) : LOWE, John, A., III [US/US]; 28 Coveside Lane, Stonington, CT 06378 (US).</p> <p>(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), + NO, PL, SE (European patent), SU, US.</p> <p>Published With international search report.</p>

(54) Title: QUINUCLIDINE DERIVATIVES



BEST AVAILABLE COPY

(57) Abstract

Quinuclidine derivatives of formulae (I), (II) or (III) and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R¹, R² and R³ are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

-1-

5

QUINUCLIDINE DERIVATIVESBackground of the Invention

This invention relates to quinuclidine derivatives. The compounds of the invention have the ability to antagonize substance P. The compounds are, therefore, useful in treating conditions such as intestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine. The present invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treating the foregoing conditions.

E.J. Warawa in U.S. Patent No. 3,560,510 refers to certain 3-amino-2-benzhydrylquinuclidines as being useful as diuretic agents, with the corresponding unsubstituted 3-benzylamino compounds acting as intermediates for same. Additionally, E.J. Warawa et al. in the Journal of Medicinal Chemistry, Vol. 18, p. 587 (1975) extends this work to other members of the series wherein the 3-amino moiety is either ethylamino, beta-phenylethylamino, beta-isopropyl-amino or 2-furfurylamino, but in no instance is there any substitution on the phenyl group itself and the 2-benzhydryl moiety is always symmetrically substituted (or unsubstituted). Neither of the aforementioned documents teaches or suggests any of these compounds to be useful as substance P antagonists.

PCT Patent Application PCT/US 89/05338, filed November 20, 1989 and assigned in common with the present application, refers to cis-3-[(cyclic)methylamino]-2-[(alpha-substituted)arylmethyl]quinuclidines, 3-[(cyclic)methylimino]-2-[(alpha-substituted)arylmethyl]quinuclidines and cis-3-[(cyclic)methyleneamino]-2-[(alpha-substituted)-arylmethyl]quinuclidines and states that they are useful as substance P antagonists. United States Patent Application 619,361, filed November 28, 1990 and assigned in common with the present application, refers to carbocyclic ring systems wherein one of the rings is substituted with an amino group and wherein one carbon atom in each of two of

-2-

the rings may be replaced by a hetero atom, and states that they are useful as substance P antagonists. (KD-cite PC 7797A).

Substance P is a naturally occurring undecapeptide
5 belonging to the tachykinin family of peptides, the latter being so-named because of their prompt stimulatory action on smooth muscle tissue. More specifically, substance P is a pharmacologically-active neuropeptide that is produced in mammals (having originally been isolated from gut) and
10 possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in U.S. Patent No. 4,680,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance
15 P has recently been shown to be involved in the transmission of pain or migraine [see B.E.B. Sandberg et al., Journal of Medicinal Chemistry, Vol. 25, p. 1009 (1982)], as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such
20 as asthma and rheumatoid arthritis, respectively, and in gastrointestinal disorders and diseases of the GI tract, like ulcerative colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache," Edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam,
25 1987, pp. 85-95).


Summary of the Invention

The present invention relates to compounds of the formula

30

35


-3-



or



wherein Y is $(CH_2)_m$ wherein m is an integer from one to
 15 three, or Y is a group of the formula



20

(hereinafter referred to as a group of the formula J);

p is an integer from zero to one;

Z is oxygen, sulfur, amino, N-(C₁-C₃) alkylamino or
 (CH₂)_n wherein n is zero, one or two;

25 R¹ is cycloalkyl having from five to seven carbon atoms,
 pyrrolyl, thienyl, pyridyl, phenyl, or substituted phenyl,
 wherein said substituted phenyl is substituted with one to
 three substituents selected from fluorine, chlorine,
 bromine, trifluoromethyl, alkyl having from one to three
 30 carbon atoms, alkoxy having from one to three carbon atoms,
 carboxy, alkoxycarbonyl having from one to three carbons in
 the alkoxy moiety and benzyloxycarbonyl;

R² is furyl, thienyl, pyridyl, indolyl, biphenyl,
 phenyl, or substituted phenyl, wherein said substituted
 35 phenyl is substituted with one or two substituents selected
 from fluorine, chlorine, bromine, trifluoromethyl, alkyl
 having from one to three carbon atoms, alkoxy having from


-4-

one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety and benzyloxycarbonyl; and

R^3 is thienyl, phenyl, fluorophenyl, chlorophenyl or
5 bromophenyl;

and the pharmaceutically acceptable salts of such compounds.

Compounds of the formula I wherein Y is a group of the formula J are depicted below.



15

Preferred compounds of the present invention are compounds of the formula II. More preferred compounds of the present invention are compounds of the formula II wherein each of R^2 and R^3 are selected from phenyl and
20 p-fluorophenyl, R^1 is selected from 2-methoxyphenyl, phenyl and 2-chlorophenyl, and Z is oxygen or $(CH_2)_n$ wherein n is zero or one.

Specific preferred compounds of the present invention are:

25 cis-8-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;

cis-8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}] decan-7-amine; and

30 cis-9-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-10-azatricyclo[4.4.1.0^{5,10}]undecane-8-amine.

Other compounds of the present invention are:

9-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-3-thia-10-azatricyclo [4.4.1.0^{5,10}]undecan-8-amine;

35 9-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-3-thia-10-azatricyclo [4.4.1.0^{5,10}]undecan-8-amine;

3-methyl-9-(diphenylmethyl)-N-((2-methoxyphenyl)-methyl)-3,10-diazatricyclo[4.4.1.0^{5,10}]undecan-8-amine;

-5-

- 3-methyl-9-(diphenylmethyl)-N-((2-chlorophenyl)-methyl)-3,10-diazatricyclo [4.4.1.0^{5,10}]undecan-8-amine;
- 3-acetyl-9-(diphenylmethyl)-N-((2-methoxyphenyl)-methyl)-3,10-diazatricyclo [4.4.1.0^{5,10}]undecan-8-amine;
- 5 3-acetyl-9-(diphenylmethyl)-N-((2-chlorophenyl)-methyl)-3,10-diazatricyclo [4.4.1.0^{5,10}]undecan-8-amine;
- 8-(diphenylmethyl)-N-((5-fluoro,2-methoxyphenyl)-methyl)-9-azatricyclo [4.3.1.0^{4,9}]decan-7-amine;
- 8-(diphenylmethyl)-N-((5-chloro,2-methoxyphenyl)-methyl)-9-azatricyclo [4.3.1.0^{4,9}]decan-7-amine;
- 10 5,6-pentamethylene-3-((5-fluoro,2-methoxy)methylamino)-2-benzhydrylquinuclidine;
- 5,6-pentamethylene-3-((5-chloro,2-methoxy)methylamino)-2-benzhydrylquinuclidine;
- 15 5,6-trimethylene-3-((5-fluoro,2-methoxy)methylamino)-2-benzhydrylquinuclidine;
- 5,6-trimethylene-3-((5-chloro,2-methoxy)methylamino)-2-benzhydrylquinuclidine;
- 9-(bis(4-fluorophenyl)methyl))-N-((2-methoxyphenyl)-methyl)-10-azatricyclo [4.4.1.0^{5,10}]undecan-8-amine;
- 20 9-(bis(4-fluorophenyl)methyl))-N-((5-fluoro,2-methoxyphenyl)methyl)-10-azatricyclo [4.4.1.0^{5,10}]undecan-8-amine;
- 2-(diphenylmethyl)dodecahydro-N-(2-methoxyphenyl)-methyl)-2H-1,4-methanobenzo[h]quinolin-3-amine;
- 25 cis-8-(diphenylmethyl)-N-(phenylmethyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- cis-8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- cis-8-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- 30 cis-8-(diphenylmethyl)-N-((2-trifluoromethylphenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- cis-8-diphenylmethyl-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.3.1.0^{4,9}]decan-9-amine;
- 35 8-(bis(4-fluorophenyl)methyl))-N-((2-chlorophenyl)-methyl)-9-azatricyclo [4.3.1.0^{4,9}]decan-7-amine; and

-6-

5,6-pentamethylene-3-((2-methoxy)methylamino)-2-(bis-(4-fluorophenyl)methyl)quinuclidine.

The compounds of formula I, formula II and formula III may contain chiral centers and therefore may exist in different isomeric forms. This invention includes all geometric isomers and stereoisomers of compounds of the formulae I, II and III, including mixtures thereof.

This invention also includes all radiolabelled forms of the compounds of the formulae I, II and III. Such radiolabelled compounds are useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays in both animal and man. Specific applications in research include radioligand binding assays, autoradiography studies and in vivo binding studies, while specific applications in the diagnostic area include studies of the substance P receptor in the human brain, such as up/down regulation in a disease state, and in vivo binding in the relevant tissues for inflammation, e.g., immune-type cells or cells that are directly involved in inflammatory bowel disorders and the like.

The present invention also relates to a pharmaceutical composition useful for treating a condition selected from gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine in a mammal (e.g., a human) in need of such treatment, comprising an amount of a compound having either formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effects of substance P at its receptor site, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating a condition selected from gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine in a mammal in need of such treatment, comprising administering to said mammal an amount of a compound having either having formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof,

-7-

effective in antagonizing the effects of substance P at its receptor site.

The present invention also relates to a method for antagonizing the effects of substance P at its receptor site in a mammal, comprising administering to such mammal an amount of a compound having either formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effects of substance P at its receptor site.

10 Detailed Description of the Invention

Compounds of the formulae I, II and III may be prepared as shown in reaction schemes 1-3 and described below.

Except where otherwise indicated, in the reaction schemes and discussion that follow, R¹, R², R³, Y, Z, m, n and p are defined as above.

-8-

SCHEME 1

5


10

15

20


25

30



-10-

SCHEME 3



-11-

Scheme 1 illustrates a method for preparing compounds of the formula II.

The starting materials used in the procedure of scheme 1, i.e. compounds of the formula XX, may be prepared from known compounds according to the procedure depicted in Scheme 2 and described below. However, those compounds of the formula XX wherein Z is $(CH_2)_n$ and n is zero are known in the art and may also be prepared as described by Schneider et al., Arch. Pharm., 309, 447 (1976).

Referring to Scheme 1, a compound of the formula XX is treated with a compound of the formula R^3CHO . This reaction is typically carried out in a reaction inert aqueous or organic solvent. Suitable solvents include water, lower alcohols, ether, tetrahydrofuran (THF), dimethylformamide (DMF), benzene, toluene, hexane, methylene chloride and chloroform. Ethanol is the preferred solvent. Preferably, the reaction is run in the presence of a basic catalyst. Sodium hydroxide is the preferred catalyst, but other bases such as alkali and alkaline earth metal hydroxides, carbonates and alkoxides, as well as organic amine bases such as trialkylamines and pyridine may also be used. Generally, the reaction is run for about 10 minutes to about 24 hours. The reaction temperature may range from about $0^\circ C$ to about $200^\circ C$, and is preferably about the reflux temperature of the solvent.

The above reaction yields a compound of the formula IV, which is then reacted with a compound of the formula R^2MgX , wherein X is chloro, fluoro, bromo or iodo, to form a compound of the formula V. This reaction is usually carried out in a reaction inert hydrocarbon, chlorohydrocarbon or ethereal solvent such as benzene, ether, toluene, hexane, THF or ethyl acetate. The preferred solvent is ether. The reaction is usually run for about 1 minute to about 10 hours. Suitable reaction temperatures range from about $-70^\circ C$ to about $100^\circ C$, with about $0^\circ C$ being preferred. The compound of formula V so formed is then converted to the corresponding desired compound of formula II by reacting it

-12-

with a compound of the formula $R^1CH_2NH_2$, and then treating the reaction mixture with a reducing agent.

The reaction of the compound of formula V with $R^1CH_2NH_2$ is typically carried out in a reaction inert hydrocarbon or chlorohydrocarbon solvent, in the presence of an acidic catalyst. Examples of solvents that may be used include hexane, benzene, toluene, chloroform, methylene chloride, ether, THF, and ethyl acetate. Examples of catalysts that may be used include mineral acids, titanium trichloride, molecular sieves and organic acids such as camphor sulfonic acid. Toluene is the preferred solvent and camphor sulfonic acid is the preferred catalyst. This reaction is generally conducted over a period of about 0.5 hours to about 24 hours, at a temperature from about room temperature to about 220°C. Preferably, the reaction temperature is about 110°C.

The reaction mixture is then treated with a reducing agent, as indicated above, to obtain the desired compound of formula II. Reducing agents that may be used include 9-borobicyclononane (9-BBN), triethylsilane and metal hydrides such as sodium borohydride and sodium triacetoxyborohydride. The preferred reducing agent is 9-BBN. Generally, the reduction is carried out in a reaction inert hydrocarbon, chlorohydrocarbon, carboxyhydrocarbon, aqueous or alcoholic solvent. Water, lower alcohols, trifluoroacetic acid, benzene, toluene, ether, hexane, THF, ethyl acetate and chloroform are suitable, with THF being preferred when the reducing agent is 9BBN. The preferred reaction temperature is about room temperature, but the reduction may be carried out at temperatures ranging from about room temperature to about 200°C.

Scheme 2 illustrates the synthesis of compounds of the formula XX, the starting materials used in the procedure of Scheme 1. Referring to Scheme 2, a compound of the formula VI is reacted with 1,3 acetonedicarboxylic acid and benzylamine in a reaction inert solvent such as water. The Ph is adjusted to about 5, e.g. by the addition of a mineral

-13-

acid, and maintained at about that value for about 0.5 to about 24 hours. The reaction is generally conducted at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about room temperature. This reaction produces a compound of the formula VII, which is then reacted with tosylmethyisocyanide in the presence of a lower alcohol such as ethanol and an alkali metal alkoxide such as potassium t-butoxide, at a temperature from about 0°C to about the reflux temperature of the solvent, preferably at about 50°C. This reaction produces a compound of the formula VIII. Suitable solvents for this reaction include dimethylsulfoxide (DMSO), dimethylformamide (DMF), ether, THF and glyme.

The compound of the formula VIII is then reacted with a lower alcohol saturated with hydrogen chloride gas. Typically, the reaction mixture is heated to reflux, water is added to the mixture, and refluxing is continued for a period of about 0.5 to about 24 hours. This reaction may be conducted to a temperature ranging from about room temperature to about the reflux temperature of the solvent, with the reflux temperature being preferred. The product of the reaction, a compound of the formula IX, is then reduced to form a compound of the formula X using ammonium formate in the presence of a noble metal catalyst such as palladium in a reaction inert solvent such as a lower alcohol. Preferably, the solvent is ethanol. The reduction may be carried out at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about the reflux temperature.


The compound of formula X so formed may be converted to a compound having formula XI by reacting it with a halogenated acetic acid ester such as ethylbromoacetate in a reaction inert solvent such as a lower alcohol, acetone, acetonitrile, THF, chloroform, hexane or toluene, at a temperature from about room temperature to about the reflux temperature of the solvent. It is preferable to use

ethylbromoacetate in ethanol and conduct the reaction at the reflux temperature.

The compound of formula XI may be converted to the corresponding desired compound of formula III in the following manner. First, it is reacted with an alkali or alkaline earth metal alkoxide, preferably potassium ethoxide, in a reaction inert hydrocarbon solvent such as toluene, benzene or hexane at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about the reflux temperature. The solvent is then evaporated and the residue taken up in a mineral acid such as dilute hydrochloric or dilute sulfuric acid. An ethereal hydrocarbon solvent, e.g. dioxane, may be added optionally as a co-solvent. This final step is also preferably conducted at the reflux temperature of the solvent, with temperatures from about room temperature to about the reflux temperature being suitable.

Compounds of the formula I may be prepared by a procedure analogous to that depicted in Scheme 1 and described above, with the exception that the starting material, rather than being a compound of the formula XX, as depicted in scheme 1, is a compound of the formula XIX, as depicted in scheme 3.

Scheme 3 illustrates the preparation of compounds of the formula XIX from known compounds. Compounds of the formula XII, the starting materials for the reaction sequence of scheme 3, have the following structure when Y is a group of the formula J:



XII
(Y=J)

This compound is known in the art and is commercially available (Aldrich®, no. 15, 503-6 (1990)).

-15-

Referring to Scheme 3, a compound of the formula XII is reacted with diethyloxylate in a reaction inert solvent such as water or a lower alcohol, preferably ethanol, in the presence of an alkali metal alkoxide or hydroxide, preferably sodium ethoxide, at a temperature from about 0°C to about the reflux temperature of the solvent, preferably at about 0°C. This reaction forms an intermediate having the formula XIII, which optionally may be isolated by filtration. If isolated by filtration, it is resuspended in the same solvent.

Treatment of the compound of formula XIII with cyanoacetamide at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about the reflux temperature, yields a compound of the formula XIV. This compound is converted to a compound of the formula XV by the following two steps. First, it is reacted with a strong mineral acid such as hydrochloric acid or sulfuric acid, preferably concentrated hydrochloric acid. Acetic acid may optionally be used as a co-solvent. This reaction is typically carried out at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about the reflux temperature. After evaporation and filtration, the resulting residue is taken up in thionyl chloride and refluxed for about 0.5 to about 6.9 hours. Excess thionyl chloride is then removed by evaporation in vacuo, and the residue treated with a lower alcohol at a temperature from about 0°C to about the reflux temperature of the solvent, preferably at about room temperature.

The compound of formula V so formed is reacted with 5-chloro-1-phenyltetrazole in a reaction inert solvent such as acetonitrile, acetone, methylene chloride or a lower alcohol or ethereal solvent, in the presence of a base such as an alkali metal hydroxide or carbonate or an organic base such as a trialkylamine. Generally, this reaction is conducted at a temperature from about room temperature to

-16-

the reflux temperature of the solvent. The reflux temperature is preferred.


The above reaction yields a compound of the formula XVI. Conversion of this compound to the corresponding compound of formula XVII, as shown in Scheme 3, is accomplished by reacting it with ammonium formate in a lower alcohol in the presence of a palladium catalyst, at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about the reflux temperature. The compound of formula XVII is then reacted with a halogenated acetic acid ester, e.g. ethyl bromoacetate. This reaction is usually carried out in a reaction inert solvent such as a lower alcohol, acetone, acetonitrile, THF, chloroform, benzene or toluene, at a temperature from about room temperature to about the reflux temperature of the solvent. It is preferable to use ethylbromoacetate in ethanol and to run the reaction at reflux. The reaction mixture is then evaporated and the residue taken up in a solvent such as water or a lower alcohol and treated with a metal hydride reducing agent such as sodium borohydride. The reaction mixture is then concentrated and subjected to hydrogenation. Generally, the hydrogenation is carried out in the presence of a noble metal catalyst such as platinum or palladium, at a hydrogen gas pressure of about 0.5 to about 100 atmospheres. Both of the above reduction steps may be carried out at a temperature from about room temperature to about the reflux temperature of the solvent, with about room temperature being preferred. The metal hydride reduction step may optionally be eliminated. It does, however, result in a higher yield.

The above reactions form a compound of the formula XVIII, which is converted to the corresponding desired compound of formula XIX as follows. The compound of formula XVIII is reacted with an alkali or alkaline earth metal alkoxide, preferably potassium ethoxide. Suitable reaction inert solvents for this reaction include hydrocarbon

-17-

solvents such as hexane, benzene and toluene. Suitable reaction temperatures range from about room temperature to about the reflux temperature of the solvent. The reflux temperature is preferred. The solvent is then evaporated and the residue taken up in a mineral acid such as dilute hydrochloric or dilute sulfuric acid. An ethereal hydrocarbon solvent such as dioxane may optionally be used as a co-solvent. Preferably, this reaction is conducted at the reflux temperature of the solvent, but temperatures ranging from about room temperature to about the reflux temperature are also suitable.

Compounds of the formula III may be prepared as illustrated and described below:



The appropriate cyclic ketone (either cyclopentanone or cyclohexanone) is reacted with benzylamine in the presence of an aqueous solution of formaldehyde and a lower alkanolic acid, preferably acetic acid, at a temperature from room temperature to about the reflux temperature of the solvent, preferably 80°C, for a period from 10 minutes to 24 hours (preferably about 2 hours). After an appropriate workup (adjusting the pH to 8 and extracting the desired product into an organic solvent such as ethyl acetate, a halogenated hydrocarbon, or hydrocarbon), the resulting residue is treated with an alcohol in the presence of an alkanolic anhydride and a strong acid such as a mineral acid, sulfuric acid or phosphoric acid. Preferably, the residue is treated with ethanol in the presence of acetic anhydride and hydrochloric acid. The reaction may be carried out at room temperature to the reflux temperature of the solvent, with room temperature being preferred, and for a period from 10

-18-

minutes to 48 hours, with 4 hours being preferred. The hydrochloric acid is preferably added after the reaction has stirred in ethanol and acetic anhydride for 2 hours, after which the reaction is stirred an additional 2 hours.

5 The foregoing reaction produces a compound of the formula XXIII, as depicted above. This compound may then be converted into a compound of the formula III by the procedure described above for converting compounds of the formula VII into compounds of the formula II, as depicted in
10 schemes 1 and 2 (i.e., reactions VII-VIII-IX-X-XI-XX in scheme 2, followed by reactions XX-IV-V-II in scheme 1).

15 Unless otherwise indicated, the reaction pressures of the foregoing reactants are not critical, e.g., a reaction pressure of about 0.5 to about 2.0 atmospheres is generally employed, with the preferred pressure usually being at or near ambient pressure (i.e., at about one atmosphere).

20 Insofar as the majority of the compounds of formulae I, II and III are basic compounds, they are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the quinuclidine base compound from the reaction mixture as a
25 pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and thereafter, subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the quinuclidine base compounds of this invention are readily prepared by
30 treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.

35 The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned quinuclidine base compounds of this invention

are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

Those compounds of the formulae I, II and III which are also acidic in nature, e.g., where R^2 is carboxyphenyl, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formulae I, II and III. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product of yields of the desired final product.

The compounds having formulae I, II and III and their pharmaceutically acceptable salts (hereinafter, also referred to as the active compounds of the present

-20-

invention) exhibit significant substance P receptor-binding activity and therefore, are of value in the treatment of a wide variety of clinical conditions which are characterized by the excess of said substance P activity. Such conditions

5 include gastrointestinal disorders such as ulcer and colitis and other like diseases of the gastrointestinal tract, central nervous system disorders such as anxiety and psychosis, inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases, respiratory

10 diseases such as asthma, as well as pain in any of the aforesaid conditions, including migraine. Hence, these compounds are readily adapted to therapeutic use as substance P antagonists for the control and/or treatment of any of the aforesaid clinical conditions in mammals,

15 including humans. The active compounds of the present invention can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in doses ranging from about 5.0 mg up to about 1500 mg per day, although variations will

20 necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of from about 0.07 mg to about 21 mg per kg of body weight per day is most desirably employed.

25 Nevertheless, variations may still occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances,

30 dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects provided that such higher dose levels are first divided into several small doses for administration

35 throughout the day.

The active compounds of the present invention may be administered alone or in combination with pharmaceutically

-21-

acceptable carriers by any one of the three routes previously indicated, and such administration can be carried out in single or multiple doses. More particularly, the novel therapeutic agents of the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the compounds are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water

-22-

ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of an active compound of the present invention in either sesame or peanut
5 oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably Ph greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are
10 suitable for intra-articular, intra-muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art. Additionally, it is also
15 possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

20 The activity of the compounds of the present invention as substance P antagonists is determined by their ability to inhibit the binding of substance P at its receptor sites in bovine caudate tissue, employing radioactive ligands to visualize the tachykinin receptors by means of
25 autoradiography. The substance P antagonist activity of the compounds is evaluated by using the standard assay procedure described by M.A. Cascieri et al., as reported in the Journal of Biological Chemistry, Vol. 258, p. 5158 (1983). This method essentially involves determining the
30 concentration of the individual compound required to reduce by 50% the amount of radiolabelled substance P ligands at their receptor sites in said isolated cow tissues, thereby affording characteristic IC_{50} values for each compound tested.

35 The anti-inflammatory activity of the compounds of the present invention is demonstrated in the standard carrageenin-induced rat foot edema test [described by C.A.

-23-

Winter et al., Proceedings of the Society of Experimental Biology and Medicine, Vol. 111, p. 544 (1962)]. In this test, anti-inflammatory activity is determined as the percent inhibition of edema formation in the hind paw of male albino rats (weighing 150-190 g) in response to a sub-plantar injection of carrageenin. The carrageenin is injected as a 1% aqueous solution. Edema formation is then assessed by measuring the volume of the injected paw initially as well as three hours after the carrageenin injection. The increase in volume three hours after carrageenin injection constitutes the individual response. Compounds are considered active if the difference in response between the drug-treated animals (six rats/group) and a control group receiving the vehicle alone is significant on comparison with the results afforded by a standard compound like phenylbutazone at 33 mg/kg, via the oral route of administration.

The anti-psychotic activity of the compounds of the present invention as neuroleptic agents for the control of various psychotic disorders is determined by a study of their ability to suppress substance P-induced hypermotility in guinea pigs. This study is carried out by first dosing the guinea pigs with a control compound or with an appropriate test compound of the present invention, then injecting the guinea pigs with substance P by intracerebral ventricular administration via canula and thereafter measuring their individual locomotor response to stimuli.

The following examples illustrate but do not limit the scope of this invention.

30

EXAMPLE 1

Cis-(1,4-ethano)-3-(phenylmethylamino)-
2-benzhydryldecahydroquinoline

A. 1-(Carboethoxymethyl)-4-(carboethoxy)-3-
decahydro-quinoline.

35

To a 1 liter round-bottomed flask equipped with condenser and N₂ inlet were added 16.38 g (81.49 mol) ethylquinoline-4-carboxylate, 27.22 g (162.98 mmol) ethyl

-24-

bromoacetate, and 400 ml ethanol. The solution was heated at reflux for 5 days, cooled, and the solvent evaporated under vacuum. The residue was taken up in 500 ml methanol, and cooled to 0°C. It was then treated with 6.19 g (162.98 mmol) sodium borohydride, and allowed to warm to room temperature. After being stirred for 1 hour at room temperature, the reaction mixture was concentrated, partitioned between methylene chloride and water, the layers separated, and the organic layer washed with water, dried, and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to afford an oil, 12.13 g (51%), which was reduced directly. The oil was taken up in 200 ml ethanol along with 2.38 ml (41.66 mmol, 1 equivalent) acetic acid and 6 g of 10% palladium on carbon, and reduced with 45 psi hydrogen for four days, adding catalyst and acetic acid to give complete reduction (total 3 ml acetic acid and 10 g catalyst). The catalyst was then filtered off, the solvent evaporated, and the residue partitioned between methylene chloride and water. The organic phase was washed with water, dried and evaporated. The residue was chromatographed on silica gel using ethyl acetate/methylene chloride as eluent to afford 6.99 g (56%) of an oil.

¹H NMR (δ , CDCl₃): 9.9-2.0 (series of multiplets, 10H), 1.14 (overlapping triplets, 6H), 2.32 (m, 1H), 2.61 (m, 1H), 2.74 (m, 2H), 3.25 (ddd, 2H), 4.0 (overlapping quartets and m, 5H).

¹³C NMR (CDCl₃): 14.2, 20.0, 21.5, 22.9, 26.1, 29.5, 39.4, 46.2, 52.9, 53.7, 57.5, 59.8, 59.9, 171.05, 174.0.

MS (%): 297 (parent, 3), 254 (16), 225 (21), 224 (100), 150 (16), 81 (10), 67 (11).

B. (1,4-Ethano)decahydroquinolin-3-one

To a 250 ml three-neck round bottomed flask equipped with condenser and N₂ inlet were added 60 ml dry toluene and 2.29 g (58.838 mol) potassium metal. The mixture was heated to reflux, and 2.71 ml (58.838 mmol) ethanol was added slowly. Refluxing was continued until all the potassium had

-25-

reacted, and then a solution of 6.99 g (23.535 mmol) 1-(carboethoxymethyl)-4-carboethoxydecahydro-quinoline in 30 ml toluene was added. The reaction mixture was refluxed for 18 hours, cooled, and the portion soluble in toluene was
5 decanted and evaporated under reduced pressure. The residues were combined and heated in 1N HCl for 24 hours. The reaction mixture was cooled, neutralized with solid sodium bicarbonate, and extracted with methylene chloride. The organic layers were combined, dried, and evaporated to
10 an oil, which was purified by chromatography on silica gel using methanol/methylene chloride as eluent to afford an oil, 1.58 g (37.5%).

¹H NMR (δ , CDCl₃): 1.1-1.5 (m, 4H), 1.6-1.9 (m, 5H), 1.95 (m, 1H), 2.09 (m, 1H), 2.10 (m, 1H, bridgehead), 2.64
15 (m, 1H), 2.84 (m, 1H), 3.15 (m, 1H), 3.27 (s, 2H).

MS (%): 180 (parent 1, 23), 179 (parent, 20), 151 (100), 136 (33), 123 (34), 122 (38), 109 (21), 108 (35), 97 (31), 96 (30), 95 (24), 82 (27), 81 (20), 70 (37), 67 (30), 55 (24).

20 C. (1,4-Ethano)-2-benzylidene-decahydroquinolin-3-one

To a 25 ml round bottomed flask equipped with condenser and N₂ inlet were added 1.58 g (8.828 mmol) (1,4-ethano)-decahydroquinolin-3-one, 1.404 g (131.242 mmol) benzaldehyde, 4.4 ml ethanol, and 0.071 g (1.765 mmol) sodium
25 hydroxide. The reaction was refluxed for 1 hour cooled, and the resulting yellow crystals collected by filtration, washed with ethanol, and dried to give 1.15 g (49%), mp 69-73C. Additional material was obtained by chromatographing the mother liquor, which was initially washed as a solution
30 in methylene chloride with sodium bisulfite, on silica gel using hexane/ethyl acetate as eluent, to give 848 mg (36%, total 85%).

¹H NMR (δ , CDCl₃): 1.1-1.9 (m, 9H), 1.9-2.2, m, 2H), 2.35 (m, 1H, bridgehead), 2.6-2.7 (m, 1H), 2.8-3.0 (m, 1H),
35 3.2-3.3 ((m, 1H), 6.89 (s, 1H), 7.23 (m, 3H), 7.94 (m, 2H).

¹³C NMR (CDCl₃): 19.0, 19.1, 19.4, 20.6, 21.8, 34.3,

-26-

40.0, 45.4, 56.6, 124.1, 128.4, 129.5, 132.1, 134.1, 146.2, 207.2 (C=O).

IR (cm⁻¹, KBr): 1709 (C=O), 1629 (C=C).

MS (%): 268 (parent +1,30), 267 (parent, 95), 239 (100), 238 (82), 170 (45), 157 (94), 156 (43), 148 (39), 130 (40), 117 (44), 116 (34), 91 (31), 67 (42), 55 (37).

D. (1,4-Ethano)-2-benzhydryl-decahydroquinolin-3-one

To a 50 ml round bottomed flask equipped with N₂ inlet were added 3.3 ml (10.044 mmol) of a 3 M solution of phenyl magnesium bromide in ether and 5 ml dry toluene. The solution was cooled to 0°C, and a solution of 1.7878 g (6.696 mmol) (1,4-ethano)-2-benzylidene-decahydroquinolin-3-one in 10 ml toluene was added dropwise. The reaction mixture was stirred at 0°C for 1.5 hours, poured into saturated aqueous ammonium chloride, and extracted into methylene chloride. The organic layer was dried and concentrated, and the residue chromatographed on silica gel using hexane/ethyl acetate as eluent to afford 1.47 g (63.6%) of an oil, as a mixture of isomers about the juncture between the cyclohexyl ring and the bicyclic nucleus.

¹H NMR (δ, CDCl₃): 1.0-2.2 (m, 11H), 2.27 and 2.33 (two multiplets, 1H, bridgehead), 2.4-3.4 (m, 3H), 4.04-4.1 (m, 1H), 4.58 and 4.75 (two doublets, 1H, benzhydryl), 7.1-7.6 (m, 10H).

¹³C NMR (CDCl₃): 18.6, 19.2, 19.3, 19.4, 19.6, 20.6, 21.1, 21.7, 22.0, 34.8, 35.5, 36.8, 42.7, 45.9, 46.1, 49.3, 50.9, 51.5, 59.4, 73.7, 74.8, 126.3, 126.5, 127.9, 128.0, 128.2, 128.3, 128.5, 128.8, 128.9, 142.5, 142.6, 143.4, 144.2, 220.0, 220.7.

MS (%): 346 (parent+1, 2.5), 318 (43), 317 (96), 274 (36), 180 (71), 167 (31), 165 (37), 150 (100), 84 (43), 49 (34).

E. Cis-(1,4-ethano)-3-(phenylmethylamino)-2-benzhydryl-decahydroquinoline

To a 25 ml round bottomed flask equipped with Dean-Stark trap, condenser, and N₂ inlet were added 702 mg (2.035

-27-

mmol) (1,4-ethano)-2-benzhydryl-decahydroquinolin-3-one, 326.7 mg (3.053 mmol) benzylamine, 20 mg camphorsulfonic acid, and 10 ml toluene. The reaction mixture was refluxed 24 hours, cooled and evaporated. The residue was taken up in 1.3 ml tetrahydrofuran and cooled to 0°C. To the stirring solution was added a 0.5 M solution (4.071 mmol) of 9-borabicyclononane in tetrahydrofuran, and the reaction allowed to warm to room temperature and stirred for 3 days. The reaction was poured into a mixture of 1N HCl and methylene chloride, the layers separated, and the aqueous layer adjusted to pH 10 with solid sodium hydroxide. The aqueous layer was then extracted with methylene chloride, and the organic layer dried and evaporated. The residue was crystallized from isopropanol to afford a white solid, 431 mg (49%), mp 125-145°C, as a mixture of isomers for the starting material.

¹H NMR (δ , CDCl₃): 1.2-2.2 (m, 10H), 2.4-3.9 (m, 9H), 4.59 (finely split doublet, 1H, benzhydryl), 6.49 (m, 2H), 7.1-7.6 (m, 13H).

¹³C NMR (CDCl₃): 15.4, 19.7, 20.0, 20.2, 20.9, 21.9, 22.0, 22.2, 22.6, 22.7, 28.7, 29.7, 31.1, 35.5, 36.6, 43.7, 49.1, 49.2, 49.7, 52.2, 52.3, 56.1, 56.7, 59.8, 63.8, 64.0, 125.6, 125.8, 126.5, 126.7, 127.9, 128.1, 128.3, 129.3, 139.9, 140.0, 143.1, 143.7, 145.2, 145.3.

MS (%): 437 (parent+1, 1), 345 (13), 270 (23), 269 (100).

Anal. Calc'd for C₃₁H₃₆N₂: C 85.27, H 8.31, N 6.42. Found: C 84.94, H 8.16, N 6.35.

EXAMPLE 2

Cis-(1,4-ethano)-3-((2-methoxyphenyl)methylamino)-2-benzhydryldecahydroquinoline

To a 25 ml round bottomed flask equipped with Dean-Stark trap, condenser, and N₂ inlet were added 769 mg (2.229 mmol) (1,4-ethano)-2-benzhydryl-decahydroquinolin-3-one, 458 mg (3.343 mmol) 2-methoxybenzylamine, 20 mg camphorsulfonic acid, and 11 ml toluene. The reaction was refluxed 24 hours, cooled, and evaporated. The residue was

-28-

taken up in 1.5 ml tetrahydrofuran and cooled to 0°C. To the stirring reaction was added a 0.5 M solution (4.458 mmol) of 9-borabicyclononane in tetrahydrofuran, and the reaction allowed to warm to room temperature and stirred 2 days. The reaction was poured into 1N HCl/methylene chloride, the layers separated, and the aqueous layer adjusted to pH 10 with solid sodium hydroxide. The aqueous layer was extracted with methylene chloride, and the organic layer was dried and evaporated. The residue was chromatographed on silica gel using methanol/methylene chloride as eluent to afford an oil, 463 mg (44.5%), again as a mixture of isomers between the cyclohexyl ring and the bicyclic nucleus.

¹H NMR (δ, CDCl₃): 1.2-2.2 (m, 10H), 2.5-4.0 (m, 9H), 3.52 and 3.56 (two singlets, 3H, OMe), 4.62 (broad doublet, 1H, benzhydryl), 6.6-6.8 (m, 2H), 7.0-7.4 (m, 12H).

¹³C NMR (CDCl₃): 14.9, 19.4, 19.7, 19.9, 20.6, 20.8, 22.0, 22.1, 22.2, 28.3, 29.5, 30.8, 35.1, 36.6, 43.6, 46.1, 46.2, 48.7, 49.8, 55.2, 55.3, 55.6, 56.1, 59.9, 63.8, 64.1, 110.0, 120.2, 120.3, 125.9, 126.6, 127.6, 127.7, 127.8, 128.0, 128.2, 128.4, 129.1, 129.2, 129.4, 129.5, 157.4, 157.5.

MS (%): 467 (parent+1, 7), 345 (60), 300 (61), 299 (100), 290 (26), 150 (21), 121 (72), 91 (78).

The oil was dissolved in ether, treated with ether saturated with HCl gas, and the solid filtered, washed with ether, and dried to afford 340 mg (26.8%), mp 176-180°C.

Anal. Calc'd for C₃₂H₃₈N₂O•2HCl•2.5H₂O: C 65.74, H 7.76, N 4.79. Found: C 65.82, H 7.81, N 4.66.

EXAMPLE 3

5,6-Trimethylene-3-((2-methoxyphenyl)methylamino)-2-benzhydryl-quinuclidine

A. 5,6-(Trimethylene)-pyridin-2-one-4-carboxylic acid

To a 250 ml round-bottomed flask equipped with N₂ inlet were added 75 ml ethanol followed by 2.37 g (0.10 g-atom) sodium. After reaction was complete, the solution was cooled to 0°C and there were added 14.98 g (0.101 mol)

-29-

diethyl oxalate and then 8.42 g (0.10 mol) cyclopentanone dropwise over 10 minutes. The reaction mixture turned to a solid yellow mass within a few minutes, and was swirled by hand intermittently for 25 minutes at 0°C. The bright
5 yellow solid was collected by filtration, then suspended in 100 ml ethanol, to which was added a hot solution of 8.41 g (0.10 mol) cyanoacetamide in 100 ml ethanol. The mixture was refluxed for 3.5 hours, cooled, and the solid filtered and washed with ethanol. The solid was then taken up in
10 water and the pH adjusted to 1.5. The resulting solid was collected (and combined with a second crop from the filtrate), taken up in 250 ml concentrated hydrochloric acid, and refluxed for 12 hours. The resulting mixture was evaporated to near dryness, and the solid collected, washing
15 with a minimal amount of water. The yield of dried product was 7.42 g (41%).

^1H NMR (δ , DMSO- d_6): 1.97 (m, 2H), 2.71 (t, 2H), 2.86 (t, 2H), 6.60 (s, 1H).

MS (%): 179 (79, parent), 151 (63), 106 (100).

20 B. Ethyl 5,6-(trimethylene)-pyridin-2-one-4-carboxylate

To a 250 ml round-bottomed flask equipped with reflux condenser and N_2 inlet were added 6.42 g 5,6-(trimethylene)-pyridin-2-one-4-carboxylic acid and 50 ml thionyl chloride. The mixture was refluxed for 1 hour (giving a solution), and
25 the excess thionyl chloride removed in vacuo. To the residue was added excess ethanol, and after stirring the resulting mixture at room temperature 5 minutes, adding more ethanol, and concentrating, the resulting solid was collected and chromatographed on silica gel using methanol/-
30 methylene chloride as eluent to give 7.173 g (83.6%) of a solid.

^1H NMR (δ , CDCl_3): 1.26 (t, 3H), 2.02 (m, 2H), 2.84 (t, 2H), 2.91 (t, 2H), 4.22 (q, 2H), 6.86 (s, 1H).

IR (cm^{-1} , KBr): 1722 and 1654 ($\text{C}=\text{O}$).

35 ^{13}C NMR (CDCl_3): 14.1, 22.5, 20.4, 30.9, 61.5, 118.0, 119.5, 140.5, 152.1, 165.1, 166.1.

MS (%): 207 (69, parent), 178 (100), 106 (37).

-30-

Anal. Calc'd for $C_{11}H_{13}NO_3$: C 63.76, H 6.32, N 6.76.
Found: C 63.85, H 6.34, N 6.65.

C. Ethyl-5,6-(trimethylene)-2-(1-phenyl-5-tetrazolyloxy)-pyridine-4-carboxylate

5 To a 500 ml round-bottomed flask equipped with condenser and N_2 inlet were added 6.97 g (33.67 mmol) ethyl-5,6-(trimethylene)-pyridin-2-one-4-carboxylate, 7.30 g (40.41 mmol) 5-chloro-1-phenyl tetrazole, 9.29 g (67.34 mmol) potassium carbonate, and 170 ml acetonitrile. The
10 mixture was refluxed for 18 hours, cooled, and most of the solvent removed in vacuo. The residue was taken up in methylene chloride, washed with water, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to give an
15 oil which was crystallized from ether/hexane 7.42 g (63%), mp 83-86.

1H NMR (δ , $CDCl_3$): 1.38 (t, 3H), 2.14 (m, 2H), 2.95 (t, 2H), 3.25 (t, 2H), 4.39 (q, 2H), 7.4-7.8 (m, 6H).

IR (cm^{-1} , KBr): 1726 (C=O).

20 ^{13}C NMR ($CDCl_3$): 14.2, 22.7, 31.1, 33.6, 61.8, 109.6, 109.7, 122.5, 129.7, 132.9, 137.6, 158.2, 159.3, 164.5, 167.5.

MS (%): 351 (7, parent), 323 (100, 295 (33), 178 (50), 132 (38), 118 (47), 117 (79), 77 (50), 65 (57).

25 Anal. Calc'd for $C_{18}H_{17}N_5O_3$: C 61.53, H 4.88, N 19.93.
Found: C 61.50, H 4.68, N 19.71.

D. Ethyl-2,3-trimethylene-pyridine-4-carboxylate

To a 250 ml round-bottomed flask equipped with condenser and N_2 inlet were added 12.77 g (36.38 mmol) ethyl-
30 5,6-(trimethylene)-2-(1-phenyl-5-tetrazolyloxy)-pyridine-4-carboxylate, 13.75 g (218.3 mmol) ammonium formate, and 182 ml ethanol. Once a solution had been obtained by stirring and heating, 12.77 g (10% palladium on carbon was added, and heating continued to reflux then the mixture was heated for
35 10 minutes at reflux followed by cooling and filtration through a diatomaceous earth (Celite trademark) pad to remove palladium. The filtrate was evaporated and the

-31-

residue taken up in methylene chloride and washed with 1N aqueous sodium hydroxide and water, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to afford an oil, 3.07 g (44%).

^1H NMR (δ , CDCl_3): 1.24 (t, 3H), 1.96 (m, 2H), 2.89 (t, 2H), 3.12 (t, 2H), 4.22 (q, 2H), 7.37 (d, 1H), 8.26 (d, 1H).

IR (cm^{-1} , KBr): 1712 (C=O).

^{13}C NMR (CDCl_3): 14.2, 22.5, 31.6, 34.0, 61.2, 120.2, 120.3, 121.0, 130.0, 133.6, 137.6, 147.8, 165.8, 167.8.

MS (%): 191 (89, parent), 162 (100), 118 (76), 117 (71), 116 (52), 91 (55), 63 (49).

Exact mass calc'd for $\text{C}_{11}\text{H}_{13}\text{NO}_2$: 191.0947. Found: 191.0928.

15 E. Ethyl-2-ethoxycarbonylmethyl-2-aza-[4.3.0]-bicyclo-nonane

To a 250 ml round-bottomed flask equipped with condenser and N_2 inlet were added 3.07 g (16.07 mmol) ethyl 2,3-trimethylene-pyridine-4-carboxylate, 5.37 g (32.15 mmol) ethyl bromoacetate, and 80 ml ethanol. The reaction mixture was refluxed for 4 days, cooled, and most of the solvent evaporated in vacuo. The residue was taken up in 80 ml methanol and treated with 1.22 g (32.15 mmol) sodium borohydride at room temperature for 14 hours. The reaction mixture was concentrated, taken up in methylene chloride, washed with water and brine, dried over sodium sulfate, and evaporated. The residue was hydrogenated with platinum oxide under 40 psi hydrogen with 1 ml acetic acid for 2 days, then filtered and concentrated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to afford an oil, 173 g (38%).

^1H NMR (δ , CDCl_3): 1.18 (m, 6H), 1.3-1.9 (m, 8H), 2.2-2.9 (multiplets, 5H), 3.20 (dd, 2H), 4.07 (m, 4H).

IR (cm^{-1} , KBr); 1720 (C=O).

35 ^{13}C NMR (CDCl_3): 14.1, 21.6, 22.8, 23.0, 30.2, 41.7, 41.9, 52.3, 55.3, 59.89, 59.94, 63.0, 170.9, 174.1.

-32-

MS (%): 284 (45, parent+1), 283 (16, parent), 210 (100), 136 (48).

Anal. Calc'd for $C_{15}H_{25}NO_4$: C 63.58, H 8.89, N 4.94.
Found: C 63.43, H 8.94, N 5.29.

5 F. 5,6-Trimethylene-2-benzylidene-3-quinuclidone

To a 125 ml round-bottomed flask equipped with a condenser and N_2 inlet were added 20 ml dry toluene and 0.705 g (18.07 g-atom) potassium. To the refluxing mixture was added 1.06 ml (18.07 mmol) ethanol, and refluxing was continued until reaction was complete. To the refluxing solution was added a solution of 2.05 g (7.23 mmol) ethyl-2-ethoxycarbonylmethyl-2-aza-[4.3.0]-bicyclononane in 20 ml toluene, and refluxing was continued for 14 hours. The reaction mixture was then cooled, the toluene decanted off the brown oil and evaporated, and the organic residues combined in 50 ml 1N HCl and refluxed for 20 hours. The reaction mixture was cooled, neutralized with solid sodium bicarbonate, and extracted with methylene chloride. The organic layer was dried over sodium sulfate and evaporated to an oil. The oil was dissolved in 3 ml ethanol, treated with 1.1 ml (10.84 mmol) benzaldehyde and 60 mg (1.44 mmol) sodium hydroxide, and refluxed for 5 minutes. The reaction mixture was then cooled, taken up in methylene chloride, washed with water, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to give 1.245 g (68%), mp 85-95°C.

1H NMR (δ , $CDCl_3$): 1.6-2.8 (series of multiplets, 11H), 3.3-3.5 (m, 2H), 7.02 (s, 1H), 7.3-7.4 (m, 3H), 8.03 (m, 2H).

IR (cm^{-1} , KBr): 1690 (C=O). ^{13}C NMR ($CDCl_3$): 19.2, 26.4, 28.1, 29.4, 37.7, 37.8, 39.7, 44.7, 61.7, 124.1, 128.4, 129.4, 132.1, 134.1, 145.7, 206.9.

MS (%): 253 (100, parent), 224 (52), 157, (55).

Anal. Calc'd for $C_{17}H_{19}NO$: C 80.60, H 7.56, N 5.53.
Found: C 80.64, H 7.45, N 5.40.

-33-

G. 5,6-Trimethylene-2-benzhydryl-3-quinuclidone

To a 50 ml round-bottomed flask equipped with N₂ inlet was added 2.4 ml (7.11 mmol) of a 3.0 M solution of phenyl magnesium bromide in ether. The solution was cooled to 0°C, and a solution of 1.2 g (4.74 mmol) of 5,6-trimethylene-2-benzylidene-3-quinuclidone in 10 ml toluene added. The reaction was stirred at room temperature for 10 minutes, poured into saturated aqueous ammonium chloride, and extracted with methylene chloride. The organic layer was dried over sodium sulfate and evaporated to an oil. The oil was chromatographed on silica gel using hexane/ethyl acetate as eluent to afford a mixture of exo and endo products as an oil, 1.054 g (67%).

¹H NMR (δ, CDCl₃): 1.3-2.6 (m, 8H), 2.8-2.9 (m, 2H), 3.1-3.6 (series of 3 multiplets, 1H each), 4.00 and 4.08 (doublets, 1H, mixture of exo and endo isomers), 4.59 and 4.65 (doublets, 1H, both isomers) 7.1-7.5 9m, 10H).

IR (cm⁻¹, KBr): 1715 (C=O).

¹³C NMR (CDCl₃): 18.9, 19.4, 26.2, 26.3, 27.7, 28.1, 29.0, 29.2, 34.6, 38.0, 39.3, 42.3, 45.1, 50.1, 51.2, 56.0, 64.7, 72.7, 73.8, 126.3, 126.4, 128.3, 128.4, 142.5, 142.6, 143.3, 143.9, 220.1, 220.6.

MS (%): 303 (41), 180 (28), 136 (100).

Exact mass calc'd for C₂₃H₂₆NO: 332.2015. Found: 332.2014.

H. 5,6-Trimethylene-3-((2-methoxyphenyl)methylamino)-2-benzhydryl-quinuclidine

To a 50 ml round-bottomed flask equipped with Dean-Stark trap, condenser, and N₂ inlet were added 0.996 g (3.01 mmol) 5,6-trimethylene-2-benzhydryl-3-quinuclidone, 0.618 g (4.51 mmol) 2-methoxybenzylamine, 3 mg camphorsulfonic acid, and 15 ml toluene. The reaction mixture was refluxed 3 days, cooled, and concentrated. The residue was taken up in 2 ml dry tetrahydrofuran and treated at 0°C with 12 ml (6.0 mmol) of a 0.5 M solution of 9-borabicyclo-nonane in tetrahydrofuran. The reaction mixture was then allowed to warm to room temperature and stirred for 4 days. It was

-34-

then poured into 1N HCl, washed with methylene chloride and the aqueous layer adjusted to pH 12 and extracted with methylene chloride. The organic layer was dried over sodium sulfate and evaporated to an oil. The oil was
5 chromatographed on silica gel using methanol/methylene chloride as eluent to afford an oil, which was converted to its hydrochloride salt using HCl gas in dry ether to give 773 mg (47%) of a white solid, mp 207-212°C.

¹H NMR (δ , CDCl₃, free base): 1.2-2.5 (m, 8H), 2.7-3.8
10 (m, 7H), 3.52 and 3.55 (singlets, 3H, for both exo and endo isomers), 4.6-4.7 (m, 1H), 6.6-6.8 (m, 3H), 7.07-7.4 (m, 10H).

¹³C NMR (CDCl₃, free base): 14.3, 21.0, 25.4, 28.0, 28.1, 28.3, 28.9, 39.0, 30.7, 33.4, 35.8, 37.5, 43.0, 46.1, 46.3,
15 48.7, 49.3, 53.6, 54.3, 54.9, 55.3, 63.5, 64.5, 110.0, 120.1, 120.2, 125.8, 126.5, 127.7, 127.8, 127.9, 128.0, 128.1, 128.3, 129.1, 129.2, 143.5, 157.4.

MS (%): 453 (1.5, parent+1), 286 (36), 285 (100), 121 (70), 91 (65).

20 Exact mass calc'd for C₃₁H₃₇N₂O: 453.2906. Found: 453.2903.

Anal. Calc'd for C₃₁H₃₇N₂O•2HCl•H₂O: C 68.50, H 7.42, N 5.15. Found: C 68.59, H 7.80, N 5.08.

EXAMPLE 4

25 5,6-Trimethylene-3-benzylamino-2-benzhydryl-quinuclidine

The title compound was prepared following the method of Example 3 in 48.9% yield as the hydrochloride salt, mp 185-189°C.

Anal. Calc'd for C₃₀H₃₄N₂•2HCl•5/4H₂O: C 69.55, H 7.49, N 5.41. Found: C 69.137, H 7.55, N 5.23.

EXAMPLE 5

8-(Diphenylmethyl)-N-((2-methoxyphenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine

A. 8-Benzylidene-9-azatricyclo[4.3.1.0^{4,9}]decan-7-one

35 To a 100 ml round-bottomed flask equipped with a condenser and nitrogen inlet were added 1.34 g (8.87 mmol) 9-azatricyclo[4.3.1.0^{4,9}]decan-7-one (prepared according to

-35-

the method of W. Schneider, B. Lang, and F. Schumann, Arch. Pharm., 309, 447 (1976)), 0.90 ml (8.87 mmol) benzaldehyde, 30 ml ethanol, and 5 pellets of sodium hydroxide. The mixture was heated at reflux for 2 hr, cooled, and
5 evaporated. The residue was taken up in ethyl acetate, washed with water, saturated aqueous sodium bisulfite solution and brine, dried over sodium sulfate, and evaporated. The resulting yellow oil, 2.07 g (100%), was crystallized from ethanol to give a yellow solid, m.p.
10 96-98°C.

¹H-NMR (δ, CDCl₃): 1.6-1.8 (m, 4H), 2.2-2.3 (m, 4H), 2.40 (m, 1H), 3.46 (m, 2H), 7.10 (s, 1H), 7.3-7.4 (m, 2H), 8.0 (m, 2H).

IR (cm⁻¹, neat): 1700, 1615 (C=O, C=C).

15 MS(%): 239 (58, parent), 211 (72), 210 (100), 117 (43), 116 (43), 84 (49).

Anal. Calc'd for C₁₆H₁₇NO: C 80.30, H 7.16, N 5.85. Found: C 80.37, H 7.18, N 5.88.

B. 8-(Diphenylmethyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-one

20 To a 100 ml three-necked round-bottomed flask equipped with a rubber septum and nitrogen inlet were added 5 ml dry toluene and 4.43 ml (13.3 mmol) of a 3.0 M solution of phenyl magnesium bromide in ether. The solution was cooled to 0°C, and a solution of 2.07 g (8.87 mmol) 8-benzylidene-
25 9-azatricyclo[4.3.1.0^{4,9}]decan-7-one in 20 ml toluene was added over 5 min. The reaction was allowed to stir at 0°C for 1 hour and then poured into saturated aqueous ammonium chloride. The mixture was extracted into ethyl acetate, and the organic layer washed with saturated aqueous ammonium
30 chloride and brine, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent and the product fractions combined to afford 1.47 g (53%) of a white solid, mp 137-138°C.

35 ¹H-NMR: (δ, CDCl₃): 1.3-2.4 (multiplets, 10H), 2.23 (m, 1H, bridgehead), 3.54 (m, 1H), 4.11 (d, J=4, 1H), 4.86 (d, J=4, 1H), 7.1-7.3 (m, 8H), 7.5 (m, 2H).

-36-

IR (cm⁻¹, CDCl₃): 1712 (C=O).

MS(%) 317 (1, parent), 289 (99), 248 (66), 198 (66), 180 (100), 179 (45), 167 (42), 165 (59), 122 (56), 91 (34), 69 (56), 54 (60).

5 Anal. Calc'd for C₂₂H₂₃NO: C 83.24, H 7.30, N 4.41.
Found: C 83.40, H 7.41, N 4.42.

C. Cis-8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine

To a 100 ml round-bottomed flask equipped with a
10 Dean-Stark trap, condenser, and nitrogen inlet were added
1.47 g (4.71 mmol) 8-(diphenylmethyl)-9-azatricyclo-
[4.3.1.0^{4,9}]decan-7-one, 0.92 ml (7.07 mmol) 2-methoxy-
benzylamine, 2 mg camphorsulfonic acid, and 15 ml toluene.
The reaction was refluxed 24 hour, cooled, and the toluene
15 evaporated. To the residue was added 18.8 ml (9.42 mmol) of
a 0.5 M solution of 9-borabicyclo[3.3.1]nonane in
tetrahydrofuran at 0°C, and the reaction allowed to warm to
room temperature and stir for 2.5 days. The reaction was
20 evaporated to one-half its original volume, and stirred at
room temperature for 2.5 days. The reaction was then
evaporated, taken up in a few ml methylene chloride, 50 ml
methanol, and 1.5 ml 6N hydrochloric acid, and allowed to
stir for 14 hours. The reaction was then evaporated, the
residue taken up in ethyl acetate, and the organic layer
25 washed with saturated aqueous sodium bicarbonate solution
and brine, dried over sodium sulfate, and evaporated. The
residue was chromatographed on silica gel using
methanol/methylene chloride as eluent, and the product
fractions combined and crystallized from isopropanol to
30 afford 540 mg (26%) of a white solid, mp 116-117°C.

¹H-NMR (δ, CDCl₃): 1.3-2.0 (series of multiplets, 8H),
2.20 (m, 1H), 2.72 (m, 1H), 3.00 (m, 1H), 3.40 (dd, J=13,96,
2H, benzylic CH₂), 3.34 (m, 1H), 3.51 (s, 3H), 3.80 (dd,
J=8.2,12, 1H, C-8H, the 8.2 Hz coupling to the adjacent C-7
35 position is consistent with a cis stereochemical
relationship), 4.46 (d, J=12, 1H), 6.5-6.8 (m, 3H), 7.0-7.3
(m, 11H).

-37-

IR (cm⁻¹, KBr): 3257 (N-H), 1600 (C=C).

MS(%): 438 (1, parent), 317 (34), 272 (33), 271 (100), 176 (19), 167 (10), 122 (24), 121 (80), 91 (59).

Anal. Calc'd for C₃₀H₃₄N₂O: C 82.15, H 7.81, N 6.39.
5 Found: C 82.08, H 7.75, N 6.39.

The title compounds of examples 6-8 were prepared using a procedure analogous to that of Example 5.

EXAMPLE 6

10 Cis-8-(diphenylmethyl)-N-(phenylmethyl)-9-azatricyclo
[4.3.1.0^{4,9}]decan-7-amine

M.p. 147-148°C, in 5% yield.

¹H-NMR (δ, CDCl₃): 0.76 (m, 1H), 1.1-2.0 (m, 7H), 2.17 (m, 1H), 2.67 (m, 1H), 2.99 (m, 1H), 3.32 (m, 1H), 3.34 (AB, J=13,112, 2H), 3.81 (dd, J=8.2,12.2, 1H), 4.38 (d, J=12.2, 15 1H), 6.58 (m, 2H), 7.0-7.4 (m, 13H).

MS(%): 408 (3.6, parent), 407 (5), 318 (17), 317 (70), 242 (18), 241 (100), 91 (34).

Anal. Calc'd for C₂₉H₃₂N₂: C 85.25, H 7.89, N 6.86.
Found: C 85.12, H 7.77, N 6.80.

20 EXAMPLE 7

Cis-8-(diphenylmethyl)-N-((2-chlorophenyl)methyl))-9-
azatricyclo[4.3.1.0^{4,9}]decan-7-amine

M.p. 159-160°C, in 12% yield.

¹H-NMR (δ, CDCl₃): 0.76 (m, 1H), 1.1-2.0 (m, 7H), 2.17 (m, 1H), 2.67 (m, 1H), 2.99 (m, 1H), 3.3 (m, 1H), 3.43 (AB, 25 J=13,90, 2H), 3.83 (m, 1H), 4.38 (d, J=12.2, 1H), 6.54 (m, 1H), 7.0-7.4 (13H).

MS(%): 317 (37), 277 (34), 275 (100), 127 (23), 125 (75).

30 Anal. Calc'd for C₂₉H₃₁N₂Cl: C 78.62, H 7.05, N 6.32.
Found: C 78.45, H 7.16, N 6.28.

EXAMPLE 8

Cis-8-(Diphenylmethyl)-N-((4-trifluoromethylphenyl)-
methyl))-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine

35 M.p. 162-163.5°C, in 25% yield.

¹H-NMR (δ, CDCl₃): 0.76 (m, 1H), 1.1-2.0 (m, 7H), 2.15 (m, 1H), 2.65 (m, 1H), 3.00 (m, 1H), 3.32 (m, 1H), 3.40 (AB,

-38-

J=13.5, 108.7, 2H), 3.82 (dd, J=8.2, 12.2, 1H), 4.35 (d, J=12.2, 1H), 6.69 (d, J=8, 2H), 7.0-7.4 (m, 12H).

MS (%): 476 (2, parent), 475 (3.5), 474 (5.5), 318 (16), 317 (65), 310 (19), 309 (100), 159 (21).

5 Anal. Calc'd for $C_{30}H_{31}N_2F_3$: C 75.61, H 6.56, N 5.88.
Found: C 75.38, H 6.55, N 5.87.

EXAMPLE 9

Cis-9-(diphenylmethyl)-N-(phenylmethyl)-10-azatricyclo[4.4.1.0^{5,10}]undecane-8-amine

10 A. N-Benzyl-9-azabicyclo[3.3.1]nonan-3-one

To a 1 L round-bottomed flask equipped with a condenser and nitrogen inlet were added 80 g (0.2 mol) of a 25% aqueous solution of glutaraldehyde, 29.2 g (0.2 mol) 1,3-acetonedicarboxylic acid, and 11.4 g (0.2 mol) benzylamine. After the initial reaction had subsided, the pH was adjusted to 5 and maintained for 14 hours. The reaction was then taken up in 6N HCl, washed with ethyl acetate, and basified with 6N sodium hydroxide solution. The aqueous layer was extracted with methylene chloride, and the organic layer filtered through diatomaceous earth (Celite [trademark]) and evaporated. The residue was chromatographed on silica gel with ethyl acetate/methylene chloride as eluent to afford 15.034 g (33%) of a pale orange solid, mp 70-73C.

25 $^1\text{H-NMR}$ (δ , CDCl_3): 1.48 (m, 4H), 1.90 (m, 2H), 2.20 (m, 2H), 2.68 (m, 2H), 3.26 (m, 2H), 3.86 (s, 2H), 7.1-7.4 (m, 5H).

IR (cm^{-1} , KBr): 1690 (C=O).

MS (%): 229 (27, parent).

30 Anal. Calc'd for $C_{15}H_{19}NO$: C 78.56, H 8.35, N 6.11.
Found: C 78.61, H 8.36, N 5.95.

B. N-Benzyl-9-azabicyclo[3.3.1]nonan-3-carbonitrile

To a 500 mL round-bottomed flask equipped with a condenser and nitrogen inlet were added 185 mL dimethoxyethane, 5.00 g (27.62 mmol) N-benzyl-9-azabicyclo[3.3.1]nonan-3-one, and 9.70 g (49.72 mmol) tosylmethylenisocyanide. The solution was cooled to 0°C, and 2.92 mL (63.53 mmol)

-39-

ethanol were added, followed by 10.83 g (96.68 mmol) potassium tert-butoxide in 4 portions. The reaction was then heated at 50°C for 10 hr, poured into a saturated sodium chloride solution, and extracted into ethyl acetate.

5 The organic layer was filtered through diatomaceous earth (Celite [trademark]) and evaporated. The residue was chromatographed on silica gel with hexane/ethyl acetate as eluent to afford an oil, 1.85 g (35%).

¹H-NMR (δ, CDCl₃): 1.45 (m, 2H), 1.68 (m, 2H), 1.84 (m, 10 2H), 2.03 (m, 2H), 2.25 (m, 2H), 2.87 (m, 2H), 3.33 (m, 1H), 3.83 (s, 2H), 7.2-7.4 (m, 5H).

¹³C-NMR (CDCl₃): 20.4, 23.6, 26.0, 30.4, 49.3, 56.6, 123.1, 127.0, 128.3, 139.5.

IR (cm⁻¹, KBr): 2220 (CN).

15 MS (%): 240 (77, parent), 172 (50), 91 (100).

High resolution mass spectrum (HRMS), Calc'd for C₁₆H₂₀N₂: 240.1622. Found: 240.1628.

C. Ethyl-N-benzyl-9-azabicyclo[3.3.1]nonan-3-carboxylate

To a 125 mL round-bottomed flask equipped with a 20 condenser and nitrogen inlet were added 1.85 g (7.72 mmol) N-benzyl-9-azabicyclo[3.3.1]nonan-3-carbonitrile and 51 mL ethanol. The solution was heated to reflux, 0.9 mL water added, and refluxing continued for 14 hr. The reaction was cooled, concentrated, and partitioned between methylene 25 chloride and a 1N aqueous sodium hydroxide solution. The organic layer was separated, dried over sodium sulfate, and evaporated. The oil was used directly without further purification, yield 80.4%.

¹H-NMR (δ, CDCl₃): 1.12 (t, J=7, 3H), 1.48 (m, 3H), 1.65 30 (m, 3H), 1.88 (m, 1H), 2.0-2.2 (m, 4H), 2.92 (m, 1H), 3.12 (m, 1H), 3.85 (s, 2H), 4.10 (q, J=7, 2H), 7.1-7.5 (m, 5H).

MS (%): 287 (24, parent), 229 (25), 214 (54), 186 (45), 173 (42), 172 (65), 170 (21), 92 (20), 91 (100), 65 (22).

D. Ethyl-9-azabicyclo[3.3.1]nonane-3-carboxylate

35 To a 125 mL round-bottomed flask equipped with a condenser and N₂ inlet were added 8.14 g (28.36 mmol) ethyl-N-benzyl-9-azabicyclo[3.3.1]nonane-3-carboxylate, 60

-40-

mL ethanol, 8.93 g (141.8 mmol) ammonium formate, and 5 g 10% palladium-on-carbon. The reaction was refluxed and fresh catalyst and ammonium formate were added until the starting material disappeared (about 4 hr, a total of 8 g catalyst). The reaction was cooled, filtered through diatomaceous earth (Celite [trademark]), and evaporated. The residue was partitioned between methylene chloride and an aqueous sodium hydroxide solution, and the organic layer separated, dried over sodium sulfate, and evaporated. The resulting oil was used directly in the next step.

MS (%): 198 (92), 197 (71, parent), 168 (63), 152 (61), 140 (67), 139 (79), 124 (91), 97 (50), 96 (100), 83 (51), 82 (96), 81 (50), 80 (52), 69 (50), 68 (61), 55 (53), 54 (43).

E. Ethyl-N-ethoxycarbonylmethyl-9-azabicyclo[3.3.1]

15 nonane-4-carboxylate

To a 250 mL round-bottomed flask equipped with a condenser and nitrogen inlet were added 5.59 g (28.36 mmol) ethyl-9-azabicyclo[3.3.1]nonane-3-carboxylate, 142 mL ethanol, and 9.47 g (56.72 mmol) ethyl bromoacetate. The reaction was refluxed 3 days, cooled, and evaporated. The residue was partitioned between methylene chloride and aqueous sodium hydroxide, and the organic layer was dried over sodium sulfate and evaporated. The residue was filtered through silica gel using ethyl acetate to afford an oil, 4.835 g (100% yield crude), as a mixture of diastereomers.

¹H-NMR (δ , CDCl₃): 1.18 (triplets, 6H), 1.2-2.4 (multiplets, 7H), 2.6-3.8 (m, 6H), 3.39, 3.47, 3.75, and 3.98 (singlets, 2H), 4.0-4.2 (quartet, 4H).

30 MS (%): 283 (15, parent), 21 (49), 210 (100), 182 (36), 168 (30), 152 (71).

F. 9-Benzylidene-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-one

To a 250 mL three-necked round-bottomed flask equipped with a condenser and nitrogen inlet were added 45 mL toluene and 1.66 g (42.72 g-atom) potassium. The reaction was heated to reflux, 1.96 mL (42.72 mmol) ethanol added slowly, and refluxing continued until the potassium disappeared. To

-41-

the refluxing reaction was then added a solution of 4.84 g (17.09 mmol) ethyl-N-ethoxycarbonylmethyl-9-azabicyclo[3.3.1]nonane-3-carboxylate in 20 mL toluene, and the reaction was refluxed 16 hr. The reaction was then cooled and evaporated, and the residue taken up in 85 mL 1N HCl and heated to reflux for 24 hr. The reaction was then cooled, extracted with methylene chloride, and the pH adjusted to 14 with sodium hydroxide. The aqueous layer was extracted with methylene chloride, and the organic layer was dried over sodium sulfate and evaporated. The resultant brown solid (1.34 g, 47.5% yield crude) was taken up in 10 mL ethanol and treated with 1.29 g (12.18 mmol) benzaldehyde and 0.065 g (1.62 mmol) sodium hydroxide. The solution was refluxed 15 min, cooled, and concentrated. The residue was partitioned between water and methylene chloride, and the organic layer separated, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel with hexane/ethyl acetate as eluent to afford 1.23 g (60%) of a solid, mp 109-112°C.

¹H-NMR (δ, CDCl₃): 1.55 (m, 3H), 1.8-2.2 (multiplets, 7H), 2.54 (m, 1H), 3.18 (m, 2H), 6.96 (s, 1H), 7.32 (m, 3H), 8.07 (m, 2H).

¹³C-NMR (CDCl₃): 12.5, 29.6, 30.0, 40.8, 50.2, 124.6, 128.4, 129.5, 132.3, 134.2, 145.1, 207.2.

IR (cm⁻¹, KBr): 1700 (C=O), 1625 (C=C).

MS (%): 254 (12), 253 (36, parent), 224 (100), 117 (19), 116 (22), 55 (20).

Anal. Calc'd for C₁₇H₁₉NO: C 80.60, H 7.56, N 5.53.

Found: C 80.64, H 7.64, N 5.48.

30 G. 9-Benzhydryl-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-one

To a 50 mL round-bottomed flask equipped with a nitrogen inlet were added 2.5 mL (7.64 mmol) of a 3M solution of phenyl magnesium bromide in ether and 10 mL toluene. The solution was cooled to 0°C, and a solution of 1.21 g (4.78 mmol) 9-benzylidene-10-azatricyclo[4.4.1.0^{5,10}]-undecan-8-one in 6 mL toluene was added dropwise. The reaction was stirred at room temperature for 15 min, then

-42-

poured into saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated. The residue was chromatographed on silica gel with hexane/ethyl acetate as eluent to afford a colorless oil, 1.028 g (65%).

$^1\text{H-NMR}$ (δ , CDCl_3): 1.1-2.1 (multiplets, 10H), 2.37 (m, 1H), 2.75 (m, 1H), 3.23 (m, 1H), 3.77 (d, $J=7$, 1H), 4.63 (d, $J=7$, 1H), 7.1-7.5 (m, 10H).

$^{13}\text{C-NMR}$ (CDCl_3): 13.2, 29.0, 29.7, 30.4, 30.8, 41.5, 45.0, 49.7, 53.1, 74.2, 126.2, 126.4, 128.0, 128.4, 128.7, 128.8, 142.6, 143.8.

IR (cm^{-1} , KBr): 1702 (C=O).

MS (%): 331 (1, parent), 304 (41), 303 (100), 262 (72), 212 (71), 180 (60), 165 (54), 136 (64), 117 (66), 83 (94), 67 (43).

HRMS, Calc'd for $\text{C}_{23}\text{H}_{25}\text{NO}$: 331.2064. Found: 331.2000.

H. Cis-9-(diphenylmethyl)-N-(phenylmethyl)-10-azatricyclo[4.4.1.0^{5,10}]undecane-8-amine

To a 25 mL round-bottomed flask equipped with a condenser, Dean-Stark trap, and nitrogen inlet were added 514 mg (1.55 mmol) 9-benzhydryl-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-one, 10 mL toluene, 249 mg (2.33 mmol) benzylamine, and 2 mg camphorsulfonic acid. The reaction was refluxed for 24 hr, cooled, and the toluene was evaporated. The residue was taken up in 1.2 mL tetrahydrofuran, cooled to 0°C, and treated with 6.22 mL (3.11 mmol) a 0.5 M solution of 9-borabicyclo[3.3.1]nonane in tetrahydrofuran. The solution was stirred at room temperature 5 days, partitioned between aqueous HCl and methylene chloride, and the aqueous layer was separated, adjusted to pH 14 with sodium hydroxide and extracted with methylene chloride. The organic layer was dried over sodium sulfate and evaporated. The residue was crystallized from 2-propanol to afford 144 mg (22%) of a white solid, mp 137-140°C.

-43-

$^1\text{H-NMR}$ (δ , CDCl_3): 1.0-1.8 (multiplets, 10H), 2.03 (m, 2H), 2.82 (m, 2H), 3.43 (AB, $J=12$, 85, 2H), 3.55 (dd, $J=9, 12$ 1H), 4.55 (d, $J=12$, 1H), 6.67 (m, 2H), 7.1-7.4 (13H).

$^{13}\text{C-NMR}$ (CDCl_3): 13.9, 23.3, 25.8, 29.9, 30.1, 30.7, 43.7, 48.8, 52.1, 53.5, 54.2, 65.2, 125.3, 126.5, 126.6, 127.7, 127.8, 128.0, 128.2, 129.2, 140.1, 143.7, 145.5.

MS (%): 421 (1, parent-1), 331 (13), 256 (28), 255 (100), 167 (12), 163 (11), 136 (12), 91 (90).

Anal. Calc'd for $\text{C}_{30}\text{H}_{34}\text{N}_2$: C 85.26, H 8.11, N 6.63.
10 Found: C 84.89, H 8.03, N 6.52.

EXAMPLE 10

Cis-9-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-10-azatricyclo[4.4.1.0^{5,10}]undecane-8-amine

The title compound was prepared using a procedure
15 analogous to that of Example 9 in 16% yield as an oil, after purification by chromatography on silica gel with methylene chloride/methanol as eluent.

$^1\text{H-NMR}$ (δ , CDCl_3): 1.0-1.8 (multiplets, 10H), 2.1 (m, 2H), 2.84 (m, 2H), 3.33 (m, 2H), 3.48 (s, 3H), 3.62 (m, 1H),
20 4.69 (m, 1H), 6.69 (m, 2H), 6.78 (m, 1H), 7.0-7.4 (m, 11H).

$^{13}\text{C-NMR}$ (CDCl_3): 13.7, 23.0, 25.38, 25.42, 29.8, 29.9, 30.5, 43.7, 46.0, 48.6, 53.9, 55.3, 110.0, 120.2, 125.3, 126.5, 127.7, 128.0, 128.2, 128.3, 128.4, 129.1, 129.2, 129.5, 129.59, 129.63, 129.7, 157.5.

25 MS (%): 452 (1, parent), 331 (21), 286 (29), 285 (100), 167 (11), 165 (14), 136 (13), 122 (12), 121 (84), 91 (63).

The hydrochloride salt was generated with HCl in ether to afford a solid, mp 219-223°C.

30 Anal. Calc'd for $\text{C}_{31}\text{H}_{36}\text{N}_2\text{O} \cdot 2\text{HCl} \cdot 3\text{H}_2\text{O}$: C 64.24, H 7.65, N 4.83. Found: C 64.61, H 7.28, N 4.86.

Example 11

Cis-9-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-3-oxa-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-amine

35 A. N-Benzyl-7-oxa-9-azabicyclo[3.3.1]nonan-3-one

Prepared by a procedure analogous to that of Example 9A in 37% yield, mp 142-147°C.

-44-

¹H-NMR (δ , CDCl₃): 2.26 (m, 2H), 2.66 (m, 2H), 3.11 (m, 2H), 3.71 (dd, J=12,42, 4H), 3.86 (s, 2H), 7.1-7.4 (m, 5H).

¹³C-NMR (CDCl₃): 40.4, 40.5, 55.4, 56.8, 71.9, 127.5, 128.6, 137.9, 207.4.

5 IR (KBr, cm⁻¹): 1695 (C=O).

MS (%): 231 (65, parent), 186 (82), 91 (100), 65 (22).

Anal. Calc'd for C₁₄H₁₇NO₂: C 72.70, H 7.41, N 6.06.

Found: C 72.65, H 7.39, N 6.03.

B. N-Benzyl-7-oxa-9-azabicyclo[3.3.1]nonan-3-carbonitrile

10 Prepared by a procedure analogous to that of Example 9B in 35% yield as an oil.

¹H-NMR (δ , CDCl₃): 1.87 (m, 2H), 2.24 (m, 2H), 2.63 (broad s, 2H), 3.82 (dd, J=12,48, 4H), 3.84 (s, 2H), 3.9-4.0 (m, 1H), 7.2-7.4 (m, 5H).

15 ¹³C-NMR (CDCl₃): 23.4, 27.0, 50.6, 50.7, 55.9, 70.6, 122.8, 127.3, 128.5, 138.2

IR (KBr, cm⁻¹): 2165 (CN).

MS (%): 243 (67), 242 (80, parent) 212 (53), 211 (84), 198 (36), 197 (96), 151 (70), 133 (45), 132 (39), 121 (37),
20 117 (38), 92 (46), 91 (100), 65 (56).

HRMS, Calc'd for C₁₅H₁₈N₂O: 242.1417. Found: 242.1427.

C. Ethyl-N-benzyl-7-oxa-9-azabicyclo[3.3.1]nonan-3-carboxylate

25 Prepared by a procedure analogous to that of Example 9C in 83% yield as an oil.

¹H-NMR (δ , CDCl₃): 1.24 (t, J=8, 3H), 1.71 (m, 2H), 2.15 (m, 2H), 2.65 (broad s, 2H), 3.65 (m, 1H), 3.84 (s, 2H), 3.85 (dd, J=12, 42, 4H), 4.13 (q, J=8, 2H), 7.1-7.4 (m, 5H).

30 ¹³C-NMR (CDCl₃): 14.3, 25.6, 37.4, 51.5, 55.9, 60.2, 71.3, 127.0, 128.3, 128.5, 138.9, 176.0.

IR (KBr, cm⁻¹): 1737 (C=O).

MS (%): 289 (20), 244 (53), 186 (61), 133 (21), 94 (22), 93 (27), 91 (100), 65 (33), 57 (41).

Anal. Calc'd for C₁₇H₂₃NO₃: C 70.56, H 8.01, N 4.84.

35 Found: C 70.61, H 8.07, N 5.01.

D. Ethyl-7-oxa-9-azabicyclo[3.3.1]nonan-3-carboxylate

Prepared by a procedure analogous to that of Example 9D in 34% yield as an oil, which was used directly in the next step.

5 E. Ethyl-N-ethoxycarbonylmethyl-7-oxa-9-azabicyclo[3.3.1]nonan-3-carboxylate

Prepared by a procedure analogous to that of Example 9E in 60% yield as an oil.

¹H-NMR (δ , CDCl₃): 1.14 (overlapping triplets, 6H), 1.65
10 (m, 2H), 1.97 (m, 2H), 2.72 (broad s, 2H), 3.39 (s, 2H),
3.54 (m, 1H), 3.80 (dd, J=12,55, 4H), 4.03 (overlapping
quartets, 2H).

¹³C-NMR (CDCl₃): 14.1, 14.2, 25.3, 36.9, 52.3, 53.4,
60.1, 60.5, 71.1, 170.7, 175.5.

15 IR (KBr, cm⁻¹): 1725-1745 (C=O's).

MS (%): 286 (39), 285 (27, parent), 240 (43), 212
(100), 182 (80), 166 (39), 129 (22), 110 (35), 108 (40), 96
(22), 94 (29), 82 (25), 81 (31), 80 (24), 70 (20), 68 (31),
67 (36), 56 (45), 55 (38), 54 (37), 53 (22).

20 Anal. Calc'd for C₁₄H₂₃NO₅•1/4H₂O: C 58.02, H 8.17, N
4.83, Found: C 57.99, H 8.29, N 5.02.

F. 9-Benzylideno-3-oxa-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-one

Prepared by a procedure analogous to that of Example 9F
25 from 3-oxa-10-azabicyclo[4.4.1.0^{5,10}]undecan-8-one, which was
prepared in 79% yield as an oil and used directly, in 89%
yield, mp 124-125°C.

¹H-NMR (δ , CDCl₃): 2.12 (m, 4H), 2.58 (m, 1H), 2.98 (m,
2H), 3.85 (dd, J=12,42, 4H), 7.00 (s, 1H), 7.2-7.4 (m, 3H),
30 8.0-8.1 (m, 2H).

¹³C-NMR (CDCl₃): 29.1, 40.6, 50.7, 71.0, 126.1, 128.5,
129.9, 132.2, 133.7, 143.3, 205.8.

IR (KBr, cm⁻¹): 1740 (C=O), 1625 (C=C).

MS (%): 255 (100, parent), 227 (61), 226 (95), 198
35 (58), 197 (92), 196 (81), 155 (67), 129 (51), 128 (64), 117
(61), 116 (73), 91 (58), 89 (64), 77 (60), 55 (61).

G. 9-(Diphenylmethyl)-3-oxa-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-one

Prepared by a procedure analogous to that of Example 9G in 36% yield, mp 140-147°C.

5 ¹H-NMR (δ, CDCl₃): 1.8-2.1 (m, 4H), 2.29 (m, 1H), 2.42 (m, 1), 2.99 (m, 1H), 3.30 (s, 2H), 3.5-3.7 (m, 3H), 4.70 (d, J=6, 1H), 7.0-7.5 (m, 10H).

¹³C-NMR (CDCl₃): 28.3, 29.9, 41.2, 46.6, 48.9, 53.1, 70.8, 71.4, 73.7, 126.5, 128.2, 128.4, 128.7, 128.8, 142.0,
10 143.4, 219.9.

H. Cis-9-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-3-oxa-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-amine

Prepared by a procedure analogous to that of Example 9H in 15% yield, mp 55-60°C.

15 ¹H-NMR (δ, CDCl₃): 1.4 (m, 1H), 1.5-1.8 (m, 3H), 2.0-2.2 (m, 2H), 2.31 (m, 1H), 2.84 (m, 1H), 3.02 (m, 1H), 3.14 (m, 1H), 3.3-3.5 (m, 3H), 3.67 (dd, J=12, 90, 2H), 3.51 (s, 3H), 4.58 (d, J=12, 1H), 6.6-6.8 (m, 2H), 7.0-7.4 (m, 12H).

¹³C-NMR (CDCl₃): 22.3, 25.7, 29.4, 45.3, 46.1, 48.5,
20 52.3, 54.1, 55.2, 64.4, 71.3, 109.9, 120.1, 125.3, 126.5, 127.8, 127.9, 129.0, 129.4, 143.2, 145.6, 157.5.

IR (KBr, cm⁻¹): 1603 (aromatic C=C).

Anal. Calc'd for C₃₀H₃₄N₂O₂•1/4H₂O: C 78.48, H 7.57, N 6.10.
Found: C 78.67, H 7.72, N 5.83.

25 EXAMPLE 12

2-(Diphenylmethyl)dodecahydro-N-(2-methoxyphenyl)methyl)-2H-1,4-methanobenzo[h]quinolin-3-amine

A. Ethyl-3-cyano-5,6-(octahydronaphtho)pyridin-2-one-4-carboxylate

30 Prepared in 46% yield as a mixture of cis and trans isomers at the saturated ring junction, mp 233-237°C.

¹H-NMR (δ, CDCl₃): 1.1-2.1 (m, 10H), 1.47 (t, J=7, 3H), 2.37 (m, 1H), 2.5-2.6 (m, 2H), 2.75 (m, 1H), 4.51 (closely overlapping quartets due to the mixture of ring junction
35 isomers, 2H).

IR (cm⁻¹, KBr): 2220 (CN), 1740 and 1648 (C=O).

-47-

MS (%): 300 (43, parent), 272 (56), 255 (100), 203 (21), 67 (20).

Anal. Calc'd for $C_{17}H_{20}N_2O_3$: C 67.98, H 6.71, N 9.33.
Found: C 67.62, H 6.70, N 9.37.

5 B. Ethyl-5,6-(octahydronaphtho)pyridin-2-one-4-carboxylate

Prepared in 23% yield as a mixture of isomers (as in part A above).

$^1\text{H-NMR}$ (δ , CDCl_3): 1.0-2.0 (m, 10H), 1.30 (t, $J=7$, 3H),
10 2.19 (m, 1H), 2.5-2.7 (m, 3H), 4.27 (q, $J=7$, 2H), 6.66 (finely split singlet, 1H).

MS (%): 276 (45), 275 (90), 274 (27, parent), 247 (33), 246 (100), 220 (57), 178 (39).

15 C. Ethyl-5,6-(octahydronaphtho)-2-(1-phenyltetrazol-5-yl)oxy)pyridine-4-carboxylate.

Prepared in 88% yield as a mixture of isomers, mp 85-98°C.

$^1\text{H-NMR}$ (δ , CDCl_3): 0.8-2.3 (multiplets, 10H), 1.31 (t, $J=7$, 3H), 2.64 (m, 1H), 2.8-2.9 (m, 2H), 3.0 (m, 1H), 4.30
20 (q, $J=7$, 2H), 5.22 (s, 1H), 7.3-7.7 (m, 5H).

$^{13}\text{C-NMR}$ (CDCl_3): 14.2, 21.9, 23.5, 25.1, 25.8, 26.0, 26.47, 26.52, 29.3, 29.5, 29.6, 29.9, 32.8, 33.7, 39.4, 42.6, 47.2, 61.8, 109.2, 109.57, 109.63, 122.4, 129.6, 129.7, 129.8, 129.9, 133.0, 142.17, 142.21, 157.4, 157.6,
25 160.7, 162.2, 165.4, 165.46, 165.49.

IR (cm^{-1} , KBr): 1720 (C=O).

MS (%): 420 (46), 419 (19, parent), 391 (56), 275 (54), 274 (100), 118 (36), 117 (63), 65 (48), 41 (33).

HRMS, Calc'd for $C_{23}H_{25}N_5O_3$: 419.1958. Found: 419.2006.

30 Anal. Calc'd for $C_{23}H_{25}N_5O_3$: C 65.86, H 6.01, N 16.70.
Found: C 65.58, H 5.97, N 16.76.

D. Ethyl-5,6-(octahydronaphtho)pyridine-4-carboxylate

Prepared in 67% combined yield for the two isomers which were separated by chromatography on silica gel; both
35 products were oils.

$^1\text{H-NMR}$ (δ , CDCl_3): (isomer 1) 1.0-2.0 (m, 10H), 1.34 (t, $J=7$, 3H), 2.32 (m, 1), 2.78 (m, 1H), 3.0-3.1 (m, 2H), 4.32

-48-

(q, J=7, 2H), 7.35 (d, J=4, 1H) 8.44 (d, J=4, 1H); (isomer 2) 1.0-2.0 (m, 10H), 1.30 (t, J=6, 3H), 2.06 (m, 1), 2.9-3.0 (m, 2H), 3.1-3.2 (m, 1H), 4.27 (q, J=6, 2H), 7.32 (d, J=5, 1H), 8.38 (d, J=5, 1H).

5 $^{13}\text{C-NMR}$ (CDCl_3): (isomer 1) 14.2, 26.2, 26.8, 27.1, 29.7, 30.3, 34.0, 39.9, 47.8, 61.3, 120.4, 131.3, 137.7, 146.4, 146.5, 161.4, 166.9; (isomer 2) 14.2, 21.6, 233.2, 25.8, 26.5, 29.9, 30.5, 33.1, 43.4, 61.3, 120.47, 120.51, 130.9, 137.7, 146.8, 162.9, 166.8.

10 IR (cm^{-1} , KBr): 1690 (C=O).

MS (%): 259 (62, parent), 230 (68), 204 (100), 186 (38), 176 (31).

E. Ethyl-1-ethoxycarbonylmethyl-(1-azatetradecahydro-phenanthrene)-4-carboxylate

15 Prepared in 14.5% yield as a mixture of isomers, as an oil.

$^1\text{H-NMR}$ (δ , CDCl_3): 1.0-2.0 (m, 10H), 1.18 and 1.21 (triplets, 6H), 2.2-2.9 (multiplets, 4H), 3.28 (s, 2H), 4.1 (quartets, 4H).

20 $^{13}\text{C-NMR}$ (CDCl_3): 14.2, 14.3, 20.5, 21.5, 24.7, 26.6, 29.2, 30.5, 32.2, 36.3, 36.6, 38.2, 49.2, 52.6, 53.5, 60.0, 60.05, 60.1, 60.15, 65.6, 171.0, 175.3)

F. 2-(Phenylmethylene)dodecahydro-2H-1,4-methanobenzo-[h]quinolin-3-one

25 Prepared as an oil in 17% yield as a mixture of isomers.

$^1\text{H-NMR}$ (δ , CDCl_3): 0.7-2.2 (m, 17H), 2.37 (finely split doublet, J=2, 1H) 2.6 (m, 1H), 3.1-3.2 (m, 2H), 6.96 (s, 1H), 7.2-7.3 (m, 3H), 8.0-8.1 (m, 2H).

30 $^{13}\text{C-NMR}$ (CDCl_3): 19.5, 19.6, 19.9, 20.2, 20.7, 20.9, 25.4, 26.3, 26.5, 26.6, 26.7, 27.5, 28.3, 29.2, 30.0, 30.8, 31.6, 32.4, 32.8, 34.2, 34.5, 35.1, 35.4, 35.9, 36.0, 39.5, 39.7, 40.1, 42.3, 45.3, 45.6, 46.1, 53.0, 59.5, 62.7, 123.9, 128.3, 129.5, 132.2, 134.2, 146.5, 207.0.

35 IR (cm^{-1} , KBr): 1702 (C=O), 1642 (C=C).

-49-

MS (%): 321 (56, parent), 293 (88), 202 (55), 172 (73), 159 (74), 157 (100), 135 (48), 130 (44), 95 (63), 91 (69), 81 (62), 79 (56), 77 (47), 67 (90), 55 (57).

HRMS, Calc'd for $C_{22}H_{27}NO$: 321.2088. Found: 321.2063.

5 G. 2-(Diphenylmethyl)dodecahydro-2H-1,4-methanobenzo[h]quinolin-3-one

Prepared in 91% yield as an oily mixture of isomers.

1H -NMR (δ , $CDCl_3$): 0.7-2.0 (m, 17H), 2.05 (m, 1H), 2.19 (m, 1H), 2.49 (m, 1H), 3.12, (m, 1H), 3.86 (d, $J=8$, 1H),
10 4.49 (d, $J=8$, 1H), 7.0-7.4 (m, 10H).

^{13}C -NMR ($CDCl_3$): 16.9, 19.4, 20.3, 21.0, 21.1, 26.0, 26.1, 26.3, 26.6, 27.7, 29.0, 30.1, 31.0, 32.0, 32.2, 33.0, 36.2, 40.6, 42.3, 42.8, 44.7, 45.2, 46.3, 47.2, 51.0, 53.4, 60.5, 73.7, 126.1, 126.3, 127.1, 127.8, 128.0, 128.2, 128.4,
15 128.58, 128.61, 128.7, 128.8, 142.4, 143.8 (carbonyl carbon too faint).

IR (cm^{-1} , KBr): 1762 (C=O).

MS (%): 399 (3, parent), 371 (36), 204 (100, 180 (68), 91 (44), 68 (32), 67 (39).

20 HRMS, Calc'd for $C_{28}H_{33}NO$: 399.2556. Found: 399.2532.

H. 2-(Diphenylmethyl)dodecahydro-N-((2-methoxyphenyl)methyl)-2H-1,4-methanobenzo[h]quinolin-3-amine

Prepared in 13% yield as a mixture of isomers, mp 145-156°C.

25 1H -NMR (δ , $CDCl_3$): 0.7-2.0 (m, 18H), 2.46 (m, 1H), 2.77 (m, 1H), 2.9-3.0 (m, 2H), 3.53 (dd, $J=14$, 96, 2H), 3.55 (s, 3H), 3.6-3.7 (m, 1H), 4.60 (d, $J=12$, 1H), 6.6-7.4 (m, 14H).

^{13}C -NMR ($CDCl_3$): 15.3, 20.1, 21.5, 26.1, 26.3, 29.9, 30.0, 30.1, 31.1, 32.1, 32.65, 32.75, 34.6, 36.2, 46.3,
30 48.7, 48.9, 55.2, 55.6, 55.7, 55.8, 64.5, 65.1, 109.9, 120.1, 125.1, 126.3, 126.4, 127.4, 127.6, 127.9, 128.18, 128.24, 128.3, 128.37, 128.44, 128.8, 129.0, 129.18, 129.26, 129.35, 129.47, 129.51, 143.2, 145.7, 157.4.

IR (cm^{-1} , KBr): 1599 (C=C).

35 MS (%): 399 (34), 354 (36), 353 (98), 344 (36), 218 (42), 204 (39), 135 (51), 122 (41), 121 (100), 92 (86), 91 (89), 81 (50), 79 (50), 77 (34), 70 (46), 69 (43), 68 (37),

-50-

67 (70), 65 (32), 56 (36), 55 (50), 77 (34), 70 (46), 69 (43), 68 (37), 67 (70), 65 (32), 56 (36), 55 (55).

HRMS, Calc'd for $C_{36}H_{45}N_2O$: 521.3528. Found: 521.3493.

Anal. Calc'd for $C_{36}H_{45}N_2O \cdot 5/4H_2O$: C 79.59, H 8.63, N 5.16. Found: C, 79.74, H 8.41, N 4.95

EXAMPLE 13

Cis-8-(diphenylmethyl)-N-(phenylmethyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine

A. N-Benzyl-3-azabicyclo[3.3.1]nonan-9-one

10 To a 2 L round-bottomed flask equipped with condenser and N_2 inlet were added 69 mL (0.638 mol) benzylamine and, dropwise, 53 mL concentrated hydrochloric acid. To the mixture obtained on stirring were added 53 mL (0.510 mol) cyclohexanone, 125 mL (0.620 mol) 37% aqueous formaldehyde
15 solution, and 730 mL acetic acid. The solution was heated at 80°C for 2 hours, then concentrated under reduced pressure. The residue was partitioned between ether and water, and the water layer was washed with ether, the pH adjusted to 8 with solid sodium carbonate, and extracted
20 with methylene chloride. The organic layer was dried over sodium sulfate and evaporated. The residue was taken up in 150 mL ethanol and treated with 50 mL (0.530 mol) acetic anhydride. After stirring for 2 hours, the solution was treated with 53 mL concentrated hydrochloric acid and
25 stirred for an additional 2 hours. It was then concentrated, taken up in water, extracted with methylene chloride, and the pH adjusted to 8 with sodium carbonate. The aqueous layer was then extracted with methylene chloride and the organic layer dried over sodium sulfate and
30 evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate as eluent to afford 8.84 g (7.6% yield) of the product as a solid, mp 47-51°C.

1H -NMR (δ , $CDCl_3$): 1.48 (m, 1H), 2.0 (m, 2H), 2.1 (m, 2H), 2.31 (broad s, 2H), 2.51 (m, 2H), 2.94 (m, 1H), 3.13
35 (m, 2H), 3.43 (s, 2H), 7.2-7.4 (m, 5H)

^{13}C -NMR ($CDCl_3$): 21.4, 34.7, 47.8, 60.3, 62.2, 127.1, 128.4, 128.6, 138.6, 218.2.

-51-

IR (KBr, cm^{-1}): 1720 (C=O).

MS (%): 230 (34), 229 (80, parent), 228 (49), 138 (55), 132 (32), 120 (73), 119 (37), 106 (37), 92 (51), 91 (100), 65 (52), 55 (47).

5 HRMS, Calc'd for $\text{C}_{15}\text{H}_{19}\text{NO}$: 229.1467. Found: 229.1465.

Anal. Calc'd for $\text{C}_{15}\text{H}_{19}\text{NO}$: C 78.56, H 8.35, N 6.11.
Found: C 78.54, H 8.29, N 6.13.

B. N-Benzyl-3-azabicyclo[3.3.1]nonan-9-carbonitrile

The title compound was prepared by procedure analogous
10 to that of Example 9B in 80% yield as a low melting solid which was a mixture of nitrile stereoisomers.

$^1\text{H-NMR}$ (δ , CDCl_3): 1.2-1.9 (m, 5H), 2.04 (m, 2H), 2.11 (doublets, $J=2$, 1H), 2.6-2.8 (m, 4H), 2.96 (doublets, $J=2$, 1H), 3.38 and 3.43 (singlets, 2H), 7.2-7.4 (m, 5H).

15 $^{13}\text{C-NMR}$ (CDCl_3): 21.18, 21.22, 26.8, 30.9, 31.7, 31.8, 31.9, 34.4, 34.8, 54.9, 58.8, 63.4, 63.5, 121.5, 126.9, 127.0, 128.3, 128.7, 138.5, 138.9.

IR (KBr, cm^{-1}): 2218 (CN).

MS (%): 240 (48, parent), 239 (43), 163 (35), 149 (66),
20 120 (33), 91 (100), 65 (38).

Anal. Calc'd for $\text{C}_{16}\text{H}_{20}\text{N}_2$: C 79.96, H 8.39, N 11.66.
Found: C 79.87, H 8.27, N 11.50.

C. Ethyl-N-benzyl-3-azabicyclo[3.3.1]nonan-9-carboxylate

The title compound was prepared in 33% yield as an oily
25 mixture of stereoisomers using a analogous procedure to that of Example 9C.

$^1\text{H-NMR}$ (δ , CDCl_3): 1.26 (overlapping triplets, 3H), 1.3-1.9 (m, 5H), 2.2-2.4 (m, 5H), 2.6-2.8 (m, 2H), 2.92 (m, 1H), 3.33 and 3.40 (singlets, 2H), 4.17 (overlapping quartets,
30 2H), 7.1-7.3 (m, 5H).

IR (KBr, cm^{-1}): 1730 (C=O).

MS (%): 287 (26, parent), 196 (82), 134 (30), 91, (100).

HRMS Calc'd for $\text{C}_{18}\text{H}_{25}\text{NO}_2$: 287.1883. Found: 287.1872.

-52-

D. Ethyl-3-azabicyclo[3.3.1]nonan-9-carboxylate

The title compound was prepared as an oil using a procedure analogous to that Example of 9D, and was used directly in the next step.

5 E. Ethyl-N-ethoxycarbonylmethyl-3-azabicyclo[3.3.1]-nonan-9-carboxylate

The title compound was prepared using a procedure analogous to that of Example 9E.

¹H-NMR (δ , CDCl₃): 1.1 (overlapping triplets, 6H), 1.4-
10 1.8 (m, 5H), 2.0-2.2 (m, 3H), 2.4-2.6 (m, 4H), 2.82 (m, 1H),
2.88 and 2.98 (singlets, 2H), 4.0 (overlapping quartets,
2H).

¹³C-NMR (CDCl₃): 14.1, 20.8, 21.0, 26.7, 30.6, 30.8,
32.4, 45.6, 46.1, 54.7, 59.2, 59.6, 59.7, 59.8, 59.9, 60.0,
15 60.1, 170.7, 170.8, 173.4, 173.5.

IR (KBr, cm⁻¹): 1735 (C=O).

MS (%): 283 (7, parent), 211 (33), 210 (100) 95 (17),
93 (17), 58 (46).

HRMS Calc'd for C₁₅H₂₅NO₄: 283.1785. Found: 283.1764.

20 F. 7-Azatricyclo[4.4.1.0^{5,10}]undecan-9-one

The title compound was prepared in 83% yield as an oil using a procedure analogous to that of Example 3F and used directly in the next step.

G. 8-Benzylidene-7-azatricyclo[4.4.1^{5,10}]undecan-9-one

25 The title compound was prepared using a procedure analogous to that of Example 3F in 75% yield, mp 133-137°C.

¹H-NMR (δ , CDCl₃): 1.3-1.6 (m, 5H), 1.9-2.0 (m, 1H),
2.25 (m, 1H), 2.34 (m, 1H), 2.8-3.1 (m, 4H), 6.99 (2, 1H),
7.2-7.4 (m, 3H), 7.99 (m, 2H).

30 ¹³C-NMR (CDCl₃): 14.2, 27.8, 29.0, 49.0, 51.9, 124.9,
128.4, 129.5, 132.1, 134.0, 144.4, 206.1.

IR (KBr, cm⁻¹): 1700 (C=O), 1621 (C=C).

MS (%): 254 (32), 253 (100 parent), 225 (76), 224
(94), 130 (33), 103 (30), 77 (43), 67 (41).

35 Anal. Calc'd for C₁₇H₁₉NO: C 80.60, H 7.56, N 5.53.
Found: C 80.57, H 7.67, N 5.49.

-53-

H. 8-(Diphenylmethyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-one

The title compound was prepared in 72% yield as an oil using a procedure analogous to that of Example 3G.

¹H-NMR (δ , CDCl₃): 1.2-1.6 (m, 4H), 1.82 (m, 1H), 2.12 (m, 1H), 2.20 (m, 1H), 2.28 (m, 1H), 2.37 (dd, J=4, 14, 1H), 2.70 (m, 1H), 2.92 (dd, J=4, 16, 1H), 3.15 (m, 1H), 3.85 (d, J=8, 1H), 4.53 (d, J=8, 1H), 7.1-7.5 (m, 10H).

¹³C-NMR (CDCl₃): 14.3, 27.6, 27.7, 28.8, 30.0, 46.1, 49.6, 50.3, 54.6, 71.5, 126.5, 126.6, 128.4, 128.5, 142.3, 143.3, 219.4.

IR (KBr, cm⁻¹): 1710 (C=O).

MS (%): 331 (2, parent), 304 (48), 303 (100) 302 (39), 223 (38), 222 (100), 180 (75), 179 (35), 167 (52), 165 (57), 136 (71), 91 (74).

Anal. Calc'd for C₂₃H₂₅NO: C 83.35, H 7.60, N 4.23. Found: C 83.89, H 7.71, N 4.27.

I. Cis-8-(diphenylmethyl)-N-(phenylmethyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine

The title compound was prepared using a procedure analogous to that of Example 3H as the hydrochloride salt in 28% yield, mp 218-222°C.

¹H-NMR (δ , CDCl₃): (free base) 1.3-1.9 (m, 9H), 2.2-2.4 (m, 2H), 2.76 (m, 2H), 2.92 (dd, J=4, 10, 1H), 3.38 (dd, J=12, 102, 2H), 3.64 (dd, J=9, 12, 1H), 4.46 (d, J=12, 1H), 6.64 (m, 2H), 7.0-7.4 (m, 13H).

¹³C-NMR (CDCl₃): 15.4, 15.8, 23.3, 29.3, 29.7, 29.9, 34.2, 36.4, 45.7, 49.7, 52.0, 55.2, 55.6, 62.6, 65.9, 126.0, 126.5, 126.6, 126.7, 127.5, 127.8, 127.9, 128.0, 128.2, 128.4, 129.3, 139.9, 143.8, 145.4.

IR (KBr, cm⁻¹): 1561 (C=C).

MS (%): 422 (<1, parent), 331 (24), 256 (29) 255 (100), 136 (922), 90 (68).

Anal. Calc'd for C₃₀H₃₄N₂•2HCl•9/4H₂O: C 67.22, H 7.61, N 5.23. Found: C 67.00, H 7.42, N 5.13.

-54-

EXAMPLE 14Cis-8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine

The title compound was prepared in 36% yield using a procedure analogous to that of Example 3H, mp 97-102°C.

¹H-NMR (δ, CDCl₃): 1.3-1.8 (m, 8H), 2.30 (m, 2H), 2.55 (m, 2H), 2.93 (dd, J=3, 10, 1H), 3.24 (m, 1H), 3.44 (dd, J=13, 84, 2H), 3.54 (s, 3H), 3.65 (dd, J=8, 12, 1H), 4.53 (d, J=12, 1H), 6.6-6.8 (m, 3H), 7.0-7.4 (m, 11H).

¹³C-NMR (CDCl₃): 15.8, 23.1, 29.3, 29.7, 29.9, 34.1, 45.6, 45.9, 49.5, 55.0, 55.1, 55.2, 62.6, 109.9, 120.1, 126.0, 126.4, 127.6, 127.7, 127.8, 127.9, 128.4, 129.1, 129.3, 143.6, 145.6, 157.4.

IR (KBr, cm⁻¹): 1600 (C=C).

MS (%): 452 (3, parent), 331 (52), 285 (100) 136 (38), 121 (54), 91 (51).

Anal. Calc'd for C₃₁H₃₆N₂O•1/2H₂O: C 80.66, H 8.08, N 6.07. Found: C 80.43, H 7.89, N 5.89.

EXAMPLE 15Cis-8-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine

The title compound was prepared using a procedure analogous to that of Example 3H in 67% yield, mp 115-118°C.

¹H-NMR (δ, CDCl₃): 1.3-1.6 (m, 5H), 1.7-1.9 (m, 3H), 2.29 (m, 2H), 2.76 (m, 2H), 2.93 (dd, J=3, 10, 1H), 3.12 (m, 1H), 3.34 (m, 1H), 3.6-3.8 (m, 2H), 4.48 (d, J=12, 1H), 6.63 (m, 1H), 7.0-7.4 (m, 13H).

¹³C-NMR (CDCl₃): 15.8, 23.3, 29.5, 29.7, 29.9, 34.5, 45.6, 48.9, 55.2, 55.6, 62.6, 126.0, 126.5, 127.5, 128.0, 128.4, 129.2, 129.8, 133.8, 137.5, 143.7, 145.5.

IR (cm⁻¹): 1599 and 1571 (C=C).

MS (%): 456 (<1, parent Cl³⁵), 331 (31), 291 (33) 289 (100), 136 (949), 127 (32), 125 (86), 91 (63).

Anal. Calc'd for C₃₀H₃₃N₂Cl: C 78.84, H 7.28, N 6.13. Found: C 78.58, H 7.19, N 6.05.

EXAMPLE 16Cis-8-(diphenylmethyl)-N-((4-trifluoromethylphenyl)-methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine

The title compound was prepared in 40% yield using a procedure analogous to that of Example 3H, mp 131-135°C.

¹H-NMR (δ, CDCl₃): 1.3-2.1 (m, 8H), 2.24 (m, 1H), 2.34 (dd, J=2, 14, 1H), 2.76 (m, 2H), 2.91 (dd, J=2, 10, 1H), 3.24 (m, 1H), 3.41 (dd, J=13, 102, 2H), 3.73 (dd, J=8, 12, 1H), 4.43 (d, J=12, 1H), 6.74 (m, 2H), 7.1-7.5 (m, 12H).

¹³C-NMR (CDCl₃): 15.7, 23.2, 29.1, 29.5, 29.8, 34.2, 45.6, 49.7, 51.4, 55.1, 55.5, 62.6, 125.1, 126.2, 126.6, 127.5, 128.0, 128.6, 128.7, 129.4, 143.6, 144.0, 144.8.

IR (KBr, cm⁻¹): 1620, 1600 (C=C).

MS (%): 490 (<2, parent), 332 (24), 331 (66), 324 (37), 323 (100), 180 (22), 159 (53), 136 (21).

Anal. Calc'd for C₃₁H₃₃N₂F₃: C 75.89, H 6.78, N 5.71.
Found: C 75.75, H 6.69, N 5.58.

EXAMPLE 17Cis-8-diphenylmethyl-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.3.1.0^{4,9}]decan-9-amineA. N-Benzyl-3-azabicyclo[3.2.1]octan-8-one

The title compound was prepared as an oil in 4% yield using a procedure analogous to that of Example 13A.

¹H-NMR (δ, CDCl₃): 1.82 (m, 2H), 2.04 (m, 2H), 2.13 (m, 2H), 2.51 (d, J=12, 2H), 2.94 (dd, J=3, 12, 2H), 3.57 (s, 2H), 7.2-7.4 (m, 5H).

¹³C-NMR (δ CDCl₃): 22.8, 45.4, 60.2, 61.7, 127.2, 128.3, 128.6, 138.8, 220.1.

MS (%): 215 (30, parent), 124 (17), 91 (100), 65 (14), 55 (16), 42 (15), 41 (17).

HRMS, Calc'd for C₁₄H₁₇NO: 215.1254. Found: 215.1316.

B. N-Benzyl-3-azabicyclo[3.2.1]octan-8-carbonitrile

The title compound was prepared as an oil in 99% yield using a procedure analogous to that of Example 9B.

¹H-NMR (δ, CDCl₃): 1.63 (m, 1H), 1.8-2.0 (m, 3H), 2.05 (d, J=11, 1H), 2.35 (m, 1H), 2.4-2.8 (m, 3H), 2.71 (dd, J=3, 11, 1H), 3.46 and 3.53 (singlets, 2H), 7.2-7.4 (m, 5H).

-56-

IR (cm^{-1} , neat): 2220 (CN).

MS (%): 226 (41, parent), 225 (31), 149 (37), 135 (59), 91 (100), 65 (34).

C. Ethyl-N-Benzyl-3-azabicyclo[3.2.1]octan-8-carbonitrile

5 The title compound was prepared using a procedure analogous to that of Example 9C in quantitative yield as an oily mixture of isomers at the 8-position:

$^1\text{H-NMR}$ (δ , CDCl_3): 1.25 (triplets, 3H), 1.6-1.8 (m, 4H), 2.02 (s, 1H), 2.10 (d, $J=8.5$, 2H), 2.3-2.5 (m, 4H), 2.72 (dd, $J=4$, 11, 2H), 3.43 and 3.48 (singlets, 2H), 4.17 (quartet, 2H), 7.1-7.4 (m, 5H).

$^{13}\text{C-NMR}$ (δ , CDCl_3): 14.2, 14.4, 27.4, 28.5, 36.7, 38.3, 49.4, 54.4, 55.2, 59.8, 60.1, 61.9, 62.3, 126.7, 126.8, 128.1, 128.6, 139.3, 139.5, 172.7, 174.0.

15 IR (cm^{-1} , neat): 1740 (C=O).

MS (%): 273 (62, parent), 272 (43), 200 (37), 182 (91), 134 (62), 92 (31), 91 (100).

D. Ethyl-N-ethoxycarbonylmethyl-3-azabicyclo[3.2.1]-octan-8-carboxylate

20 The title compound was prepared by a procedure analogous to that of Example 9E in 75% overall yield as an oily mixture of isomers at the 8-position:

$^1\text{H-NMR}$ (δ , CDCl_3): 1.10 (triplets, 6H), 1.5-1.7 (m, 4H), 2.19 (s, 1H), 2.3-2.5 (m, 4H), 2.6 (m, 2H), 3.00 and 3.09 (singlets, 2H), 4.0 (quartets, 4H).

$^{13}\text{C-NMR}$ (δ , CDCl_3): 14.08, 14.15, 14.19, 27.0, 28.1, 36.3, 38.0, 48.6, 53.6, 54.5, 58.1, 58.7, 59.1, 59.7, 60.0, 170.6, 172.3, 173.7.

IR (cm^{-1} , neat): 1737 (C=O).

30 MS (%): 269 (15, parent), 196 (100), 81 (34), 79 (36), 58 (55), 57 (37).

Anal. Calc'd for $\text{C}_{14}\text{H}_{23}\text{NO}_4 \cdot 1/4\text{H}_2\text{O}$: C 61.41, H 8.65, N 5.11. Found: C 61.53, H 8.69, N 5.07.

E. 7-Azatricyclo[4.3.1.0^{4,9}]decan-9-one

35 The title compound was prepared as an intermediate by a procedure analogous to that of Example 13F in 74% yield, and used without further characterization.

-57-

F. 8-Benzylidene-7-azatricyclo[4.3.1.0^{4,9}]decan-9-one

The title compound was prepared by a procedure analogous to that of Example 3F in 87% yield, mp 134-140°C.

¹H-NMR (δ, CDCl₃): 1.67 (m, 2H), 1.95 (m, 2H), 2.42 (m, 1H), 2.49 (m, 2H), 2.69 (m, 2H), 3.17 (m, 2H), 6.93 (s, 1H), 7.2-7.4 (m, 3H), 7.98 (m, 2H).

¹³C-NMR (δ, CDCl₃): 32.8, 38.9, 52.3, 58.5, 123.1, 128.4, 129.5, 132.3, 133.9, 144.3, 205.6.

IR (cm⁻¹, KBr): 1700 (C=O), 1630 (C=C).

MS (%): 239 (100, parent), 211 (75), 210 (96), 182 (32), 156 (30), 130 (33), 116 (31), 77 (33).

Anal. Calc'd for C₁₆H₁₇NO: C 80.30, H 7.16, N 5.85. Found: C 80.36, H 6.91, N 5.58.

G. 8-Diphenylmethyl-7-azatricyclo[4.3.1.0^{4,9}]decan-9-one

The title compound was prepared as an oil in 38% yield by a procedure analogous to that of Example 3G.

¹H-NMR (δ, CDCl₃): 1.55 (m, 1H), 1.65 (m, 1H), 1.89 (m, 2H), 2.11 (m, 1H), 2.25 (m, 1H), 2.43 (m, 1H), 2.51 (m, 1H), 2.65 (m, 1H), 2.92 (m, 1H), 3.30 (m, 1H), 3.81 (d, J=8, 1H), 4.50 (d, J=8, 1H), 7.1-7.5 (m, 10H).

¹³C-NMR (δ, CDCl₃): 32.7, 38.5, 40.2, 50.3, 52.3, 52.6, 60.8, 71.2, 126.47, 126.52, 128.4, 128.5, 128.6, 142.2, 143.2, 219.3.

IR (cm⁻¹, neat): 1715 (C=O).

MS (%): 317 (6, parent), 289 (96), 222 (100), 213 (56), 184 (54), 180 (53), 167 (50), 165 (55), 152 (59), 122 (62), 91 (91), 79 (55), 67 (53), 55 (52).

Anal. Calc'd for C₂₂H₂₃NO: 317.1812. Found: 317.1764.

H. Cis-8-diphenylmethyl-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.3.1.0^{4,9}]decan-9-amine

The title compound was prepared in 33% yield by a procedure analogous to that of Example 3H, mp 147-151°C.

¹H-NMR (δ, CDCl₃): 1.3-1.6 (m, 2H), 1.6-1.8 (m, 2H), 2.02 (m, 3H), 2.1-2.4 (m, 3H), 2.98 (m, 1H), 3.13 (m, 1H), 3.5 (dd, 2H), 3.57 (s, 3H), 3.6 (m, 1H), 4.52 (d, J=12, 1H), 6.6-6.8 and 7.1-7.4 (m, 14H).

-58-

^{13}C -NMR (δ , CDCl_3): 30.7, 31.5, 32.7, 34.5, 38.6, 46.4, 49.4, 49.6, 53.0, 55.2, 60.4, 62.8, 110.0, 120.1, 125.8, 126.3, 127.7, 128.2, 128.3, 129.0, 129.4, 143.5, 145.5, 145.7, 157.4.

5 IR (cm^{-1} , KBr): 1602 (C=C).

MS (%): 438 (1, parent), 317 (46), 272 (30), 271 (100), 121 (62), 91 (61).


Anal. Calc'd for $\text{C}_{30}\text{H}_{34}\text{N}_2\text{O} \cdot 1/2\text{H}_2\text{O}$: C 80.50, H 7.88, N 6.26. Found C 80.86, H 7.77, N 6.18.

10

-59-


CLAIMS

1. A compound of the formula



or

10



III

15

wherein Y is $(CH_2)_m$ wherein m is an integer from one to three, or Y is a group of the formula



p is an integer from zero to one;

Z is oxygen, sulfur, amino, N-(C₁-C₃) alkylamino or
25 -(CH₂)_n- and n is zero, one or two;

Ar is thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl;

R¹ is cycloalkyl having from five to seven carbon atoms, pyrrolyl, thienyl, pyridyl, phenyl or substituted phenyl,
30 wherein said substituted phenyl is substituted with one to three substituents selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbons in
35 the alkoxy moiety and benzyloxycarbonyl; and

R² is furyl, thienyl, pyridyl, indolyl, biphenyl, phenyl or substituted phenyl, wherein said substituted phenyl is

-60-

substituted with one or two substituents selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety and benzyloxycarbonyl,

or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1 of the formula I which is of the cis-configuration.

10 3. A compound as claimed in claim 1 of the formula II which is of the cis-configuration.

4. A compound as claimed in claim 2 wherein m is one.

5. A compound as claimed in claim 2 wherein m is two.

6. A compound as claimed in claim 3 wherein Z is
15 oxygen.

7. A compound as claimed in claim 3 wherein Z is $-(CH_2)_n-$ and n is zero.

8. A compound as claimed in claim 4 wherein Ar, R¹ and R² are each phenyl.

20 9. A compound as claimed in claim 4 wherein Ar is phenyl, R¹ is 2-chlorophenyl and R² is phenyl.

10. A compound as claimed in claim 4 wherein Ar is phenyl, R¹ is 2-trifluoromethylphenyl and R² is phenyl.

11. A compound as claimed in claim 4 wherein Ar is
25 phenyl, R¹ is 2-methoxyphenyl and R² is phenyl.

12. A compound as claimed in claim 5 wherein Ar, R¹ and R² are each phenyl.

13. A compound as claimed in claim 5 wherein Ar is phenyl, R¹ is 2-chlorophenyl and R² is phenyl.

30 14. A compound as claimed in claim 5 wherein Ar is phenyl, R¹ is 2-trifluoromethylphenyl and R² is phenyl.

15. A compound as claimed in claim 5 wherein Ar is phenyl, R¹ is 2-methoxyphenyl and R² is phenyl.

16. A compound as claimed in claim 7 wherein Ar, R¹ and
35 R² are each phenyl.

17. A compound as claimed in claim 7 wherein Ar is phenyl, R¹ is 2-chlorophenyl and R² is phenyl.

-61-

18. A compound as claimed in claim 7 wherein Ar is phenyl, R¹ is 4-trifluoromethylphenyl and R² is phenyl.

19. A compound as claimed in claim 7 wherein Ar is phenyl, R¹ is 2-methoxyphenyl and R² is phenyl.

5 20. A compound as claimed in claim 1 wherein said compound is 8-benzhydryl-N-phenylmethyl-9-azatricyclo[4.3.-1.0^{4,9}]decan-7-amine.

21. A compound as claimed in claim 1 wherein said compound is 8-benzhydryl-N-[(2-chlorophenyl)methyl]-9-aza-
10 tricyclo[4.3.1.0^{4,9}]decan-7-amine.

22. A compound as claimed in claim 1 wherein said compound is 8-benzhydryl-N-[(4-trifluoromethylphenyl)methyl]-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine.

23. A compound as claimed in claim 1 wherein said
15 compound is 8-benzhydryl-N-[(2-methoxyphenyl)methyl]-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine.

24. A pharmaceutical composition useful for treating a condition selected from gastrointestinal disorders, central nervous system disorders, inflammatory diseases,
20 pain and migraine in a mammal, comprising an amount of a compound as claimed in claim 1 effective in antagonizing the effect of substance P at its receptor site and a pharmaceutically acceptable carrier.

25. A method of treating a condition selected from
25 gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound as claimed in claim 1 effective in antagonizing the effect of substance P at its
30 receptor site.

26. A method for treating a disease or condition medicated by an excess of substance p in a mammal, comprising administering to a mammal in need of such treatment a compound as claimed in claim 1 in an amount that
35 is effective in antagonizing the effects of substance P at its receptor site.

-62-

27. A compound as claimed in claim 1, where said compound is selected from:


- cis-(1,4-ethano)-3-(phenylmethylamino)-2-benzhydryldecahydroquinoline;
- 5 cis-(1,4-ethano)-3-((2-methoxyphenyl)methylamino)-2-benzhydryldecahydroquinoline;
- 5,6-trimethylene-3-((2-methoxyphenyl)methylamino)-2-benzhydryl-quinuclidine;
- 5,6-trimethylene-3-benzylamino-2-benzhydryl-quinuclidine;
- 10 8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;
- 8-(diphenylmethyl)-N-(phenylmethyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;
- 15 8-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;
- 8-(diphenylmethyl)-N-((4-trifluoromethylphenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;
- cis-8-(phenylmethyl)amino-9-benzhydryl-10-azatricyclo-
- 20 [4.4.1.0^{5,9}]undecane;
- 2-(diphenylmethyl)dodecahydro-N-(2-methoxyphenyl)-methyl)-2H-1,4-methanobenzo[h]quinolin-3-amine;
- cis-8-(diphenylmethyl)-N-(phenylmethyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- 25 cis-8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- cis-8-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- cis-8-(diphenylmethyl)-N-((4-trifluoromethylphenyl)-
- 30 methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;
- cis-8-diphenylmethyl-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.3.1.0^{4,9}]decan-9-amine;
- cis-8-((2-methoxyphenyl)methyl)amino-9-benzhydryl-10-azatricyclo[4.4.1.0^{5,10}]undecane; and
- 35 cis-9-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-3-oxa-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-amine.

-63-


28. A radioactive isotope of a compound according to claim 1, said radioactive isotope being selected from the group consisting of the tritium and C^{14} isotopes of said compound.

5

29. A process for preparing a compound of the formula



or



20 wherein Y is $(CH_2)_m$ wherein m is an integer from one to three, or Y is a group of the formula



p is an integer from zero to one;

Z is oxygen, sulfur, amino, N-(C_1-C_3) alkylamino or $-(CH_2)_n-$ and n is zero, one or two;

30 Ar is thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl;

R^1 is cycloalkyl having from five to seven carbon atoms, pyrrolyl, thienyl, pyridyl, phenyl or substituted phenyl, wherein said substituted phenyl is substituted with one to
35 three substituents selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms,

-64-


carboxy, alkoxycarbonyl having from one to three carbons in the alkoxy moiety and benzyloxycarbonyl; and

R^2 is furyl, thienyl, pyridyl, indolyl, biphenyl, phenyl or substituted phenyl, wherein said substituted phenyl is substituted with one or two substituents selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety and benzyloxycarbonyl,


or a pharmaceutically acceptable salt thereof,

comprising: (a) reacting a compound of the formula $R^1CH_2NH_2$, wherein R^1 is defined as above, with, respectively,

(i) a compound of the formula




wherein Y, R^2 and R^3 are defined as above, or (ii) a compound of the formula




35 wherein Z, R^2 and R^3 are defined as above, or (iii) a compound of the formula

-65-




wherein p , R^2 and R^3 are defined as above, and then (b) reducing the product formed in step (a).

- 10 30. A process according to claim 29, wherein said compound of the formula I', V or III', as depicted and defined in claim 29, is obtained by reacting a compound of the formula R^2MgX , wherein R^2 is defined as in claim 29 and X is chloro, fluoro, bromo or iodo, with, respectively,
- 15 (i) a compound of the formula




- 25 wherein Y and R^3 are defined as in claim 29, (ii) a compound of the formula



- 35 wherein Z and R^3 are defined as in claim 29, or (iii) a compound of the formula

-66-



III'

5

wherein p and R³ are defined as in claim 29.

31. A process according to claim 29 or claim 30,
10 wherein said process yields a compound of the formula I, as depicted and defined in claim 1.

32. A process according to claim 29 or claim 30,
wherein said process yields a compound of the formula II, as depicted and defined in claim 1.

15 33. A process according to claim 29 or claim 30,
wherein said process yields a compound of the formula III, as depicted and defined in claim 1.

34. A process according to claim 29 or claim 30,
wherein said process yields a compound of the formula I or
20 II, as depicted and defined in claim 1, which is of the cis configuration.

35. A process according to any of claims 29-31,
wherein said process yields a compound of the formula I
wherein Y is (CH₂)_m and m is one or two.

25 36. A process according to any of claims 29, 30 and
32, wherein said process yields a compound of the formula II
wherein X is oxygen and n is zero.

37. A process according to claim 29 or claim 30,
wherein said process yields a compound selected from the
30 group consisting of:

cis-(1,4-ethano)-3-(phenylmethylamino)-2-benzhydryldecahydroquinoline;

cis-(1,4-ethano)-3-((2-methoxyphenyl)methylamino)-2-benzhydryldecahydroquinoline;

35 5,6-trimethylene-3-((2-methoxyphenyl)methylamino)-2-benzhydryl-quinuclidine;

5,6-trimethylene-3-benzylamino-2-benzhydryl-quinuclidine;

8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;

5 8-(diphenylmethyl)-N-(phenylmethyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;

8-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;

10 8-(diphenylmethyl)-N-((4-trifluoromethylphenyl)methyl)-9-azatricyclo[4.3.1.0^{4,9}]decan-7-amine;

cis-8-(phenylmethyl)amino-9-benzhydryl-10-azatricyclo[4.4.1.0^{5,9}]undecane;

2-(diphenylmethyl)dodecahydro-N-(2-methoxyphenyl)methyl)-2H-1,4-methanobenzo[h]quinolin-3-amine;

15 cis-8-(diphenylmethyl)-N-(phenylmethyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;

cis-8-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;

20 cis-8-(diphenylmethyl)-N-((2-chlorophenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;

cis-8-(diphenylmethyl)-N-((4-trifluoromethylphenyl)methyl)-7-azatricyclo[4.4.1.0^{5,10}]undecan-9-amine;


cis-8-diphenylmethyl-N-((2-methoxyphenyl)methyl)-7-azatricyclo[4.3.1.0^{4,9}]decan-9-amine;

25 cis-8-((2-methoxyphenyl)methyl)amino-9-benzhydryl-10-azatricyclo[4.4.1.0^{5,10}]undecane; and

cis-9-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-3-oxa-10-azatricyclo[4.4.1.0^{5,10}]undecan-8-amine.

International Application No.

PCT/US 91/03369

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁹		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl. 5	C 07 D 453/00	C 07 D 471/18
C 07 D 513/18	A 61 K 31/435	A 61 K 31/495
A 61 K 31/535	A 61 K 31/535	A 61 K 31/535
A 61 K 31/535 (C 07 D 471/18, 241:00, 221:00, 221:00)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int. Cl. 5	C 07 D 453/00	C 07 D 471/00
	C 07 D 513/00	A 61 K 31/00
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 18, no. 6, June 1975, (Washington, DC, US), E.J. WARAWA et al.: "Quinuclidine chemistry. 4. Diuretic properties of cis-3-amino-2-benzhydrylquinuclidine," pages 587-593, see scheme I; abstract (cited in the application) ---	1,24
A	WO,A,9005729 (PFIZER) 31 May 1990, see claims 1,33 (cited in the application) ---	1,24
A	ARCHIV der PHARMAZIE, vol. 309, no. 6, June 1976, Verlag Chemie, (Weinheim, DE), W. SCHNEIDER et al.: "Nortropan-3beta-essigsäure, Tropachinuclidin und Dehydrotropachinuclidin", pages 447-457, see abstract; page 450, compounds 15,17-20 (cited in the application) -----	1
¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
23-08-1991	16. 10. 91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 Nuria TORIBIO	

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 91/03369

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁵ : (C 07 D 471/18, 221:00, 221:00, 209:00), (C 07 D 471/18, 221:00, 221:00, 221:00), (C 07 D 498/18, 265:06, 221:00, 221:00)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System ¹	Classification Symbols	
IPC ⁵		
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE		

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 91/03369

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : (C 07 D 513/18, 279:00, 221:00, 221:00)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System :	Classification Symbols	
IPC ⁵		
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1 ☒ Claim numbers 25, 26 because they relate to subject matter not required to be searched by this Authority, namely see PCT-Rule 39.1(iv)
- 2 ☐ Claim numbers because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically
- 3 ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a)

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

- 1 ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
- 2 ☐ As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:
- 3 ☐ No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
- 4 ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest
- ☐ No protest accompanied the payment of additional search fees

US 9103369
SA 48038

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

02:34:11 \M301 6.1.1

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)